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Abstract 
In this study, simple spectrophotometric methods were developed for the assay 
of tobramycin and cefadroxil in their bulk and pharmaceutical dosage forms. 
Objectives : 
 Simple spectrophotometric methods were developed for determination 
of tobramycin and cefadroxil in pure bulk form and pharmaceutical 
formulations. 
Methodology: 
The colorimetric method for tobramycin was based on the coupling of 
tobramycin with ascorbic acid as a chromogen, while the spectrophotometric 
method for cefadroxil was based on the hydrolysis of cefadroxil with sodium 
hydroxide (1N). 
Results: 
It has been established that tobramycin reacts with ascorbic acid to form 
a water soluble coloured 1:1 complex with two maximum wave lengths at 390 
nm and 532nm, while cefadroxil reacts with sodium hydroxide to form a 
colored product with maximum absorbance at 342 nm. For the proposed 
methods the color developed after heating for 30 minutes and remained stable 
for at least 24 hours. The optimum conditions for the proposed methods was 
investigated and incorporated into the procedure. The validity of the proposed 
methods was tested by analyzing samples of tobramycin and cefadroxil under 
the optimum experimental conditions employed. Beer’s law was found to be 
valid over the concentration range 2.8 X 10-05- 14 X 10-05M and 1.38 X 10-05- 
 iv
6.9 X 10-05M for tobramycin and cefadroxil respectively. Regression analysis 
of Beer’s plot showed good correlation (R2 = 0.9986) for tobramycin and (R2 = 
0.9991) for cefadroxil, with a detection limit of 8.9 X 10-06 M (5.08µg/ml) 
and1.9 X 10-06M (0.693µg/ml) respectively. The precision of the methods was 
determined on three different concentrations of tobramycin and cefadroxil. The 
results showed a low standard deviation (SD) which varied from 2.3 X 10-03 -5 
X 10-03(tobramycin) and 1.15 X 10-03 -5.8 X 10-03 (cefadroxil) in the range 5.6 
X 10-05- 11.8 X 10-05M and 2.75 X 10-05- 5.52 X 10-05M respectively. The assay 
results for commercial tobramycin injections were 99.5±0.59% and for eye 
drops were 50.5±0.53% and 92.1±0.38% for Tobradex® and Tobrex® 
respectively.The assay results for commercial cefadroxil capsules were 
99.6±1.19% (Midroxil®), 102.7±1.08% (Ibidroxil®) and 101.13± 0.25% 
(Longicef®). 
 The added recovery% was 100.9±2.252for the commercial tobramycin 
injections and 99.37±0.23 for the commercial cefadroxil capsuleswhich 
reflected no interference by the injections and capsules excipients. The results 
obtained were sufficiently accurate and reproducible. 
A proposed scheme for the reaction of tobramycin with ascorbic acid is 
given.  
Conclusion:   
The results of the assay for tobramycin were 99.5±0.59% and for 
cefadroxil were99.6±1.19% (Midroxil®), 102.7±1.08% (Ibidroxil®) and 
101.13± 0.25% (Longicef®), with good precision, accuracy and good recovery 
%. 
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  ﻣﻠﺨﺺ اﻷﻃﺮوﺣﺔ
 :اﻻهﺪاف 
 ِﻟﻌﻘﺎر اﻟﺘﻮﺑﺮاﻣﻴﺴﻴﻦ ﻓﻲ هﺬﻩ اﻟﺪراﺳﺔ ﻃﺮﻳﻘﺔ ﻃﻴﻔﻴﺔ ﺑﺴﻴﻄﺔ ﻟﻠﺘﺤﻠﻴﻞ اﻟﻜﻤﻲ أﺳﺘﺨﺪﻣﺖ
  .ﻓﻲ ﺻﻮرﺗﻪ اﻟﻨﻘﻴﺔ واﻟﺼﻴﺎﻏﺎِت اﻟﺼﻴﺪﻻﻧﻴِﺔ اﻟﺴﻴﻔﺎدروآﺴﻴﻞو
  :ﻃﺮق اﻟﻌﻤﻞ
ﺎدة ﻣﻠﻮﻧﺔ ﻋﻨﺪ  َﺗﺴﺘﺨﺪُم اﻷﺳﻜﻮرﺑﻴﻚ أﺳﻴﺪ آﻤ ﻟﻠﺘﻮﺑﺮاﻣﻴﺴﻴﻦ  ﻃﺮﻳﻘﺔ اﻟﺘﺤﻠﻴﻞ اﻟﻠﻮﻧﻲ
 ﺗﻌﺘﻤﺪ ﻋﻠﻰ اﻟﺘﺤﻠﻴﻞ  ﻟﻠﺴﻴﻔﺎدروآﺴﻴﻞﻃﺮﻳﻘﺔ اﻟﺘﺤﻠﻴﻞ اﻟﻄﻴﻔﻰ، ﺑﻴﻨﻤﺎ ﺮاﻣﻴﺴﻴﻦﺑاﻻﻗﺘﺮان ﺑﺎﻟﺘﻮ
 ﻋﻨﺪ درﺟﺔ ﺣﺮارة )N1(اﻟﻤﺒﺎﺷﺮ ﻟﻠﺴﻴﻔﺎدروآﺴﻴﻞ ﺑﻌﺪ ﺗﻔﺎﻋﻠﻪ ﻣﻊ هﻴﺪروآﺴﻴﺪ اﻟﺼﻮدﻳﻮم 
  Cº001
  :اﻟﻨﺘﺎﺋﺞ
  1:1 ﺑﻨﺴﺒﺔ ﻟﻘﺪ وﺟﺪ ﺑﺄّﻧﺎﻟﺘﻮﺑﺮاﻣﻴﺴﻴﻦ ﻳﺘﻔﺎﻋﻞ َﻣﻊ اﻷﺳﻜﻮرﺑﻴﻚ أﺳﻴﺪ ﻟَﺘﺸﻜﻴﻠﻤﻌﻘﺪ ﻣﻠّﻮِن
،  ﻧﺎﻧﻮﻣﺘﺮ235ﻧﺎﻧﻮﻣﺘﺮو 093ﻗﺎﺑﻞ ﻟﻠﺬوﺑﺎِن  ِ ﻓﻲ اﻟﻤﺎء  ذو اﻣﺘﺼﺎﺻﻴﺔ ﻗﺼﻮى ﻋﻨﺪ
اﻟﺴﻴﻔﺎدروآﺴﻴﻞ ﻳﺘﻔﺎﻋﻞ َﻣﻊ هﻴﺪروآﺴﻴﺪ اﻟﺼﻮدﻳﻮم ﻟﺘﺸﻜﻴﻞ ﻧﺎﺗﺞ ذو اﻣﺘﺼﺎﺻﻴﺔ ﻗﺼﻮى ﺑﻴﻨﻤﺎ
 42 دﻗﻴﻘﺔ وﻳﺪوم ﻋﻠﻰ اﻻﻗﻞ  ﻟﻤﺪة 03ﻳﺘﻜﻮن اﻟﻠﻮن ﺑﻌﺪ اﻟﺘﺴﺨﻴﻦ ﻟﻤﺪة . ﻧﺎﻧﻮﻣﺘﺮ243ﻋﻨﺪ 
 ﺗﻢ اﺧﺘﺒﺎر اﻟﻈﺮوف اﻟﻤﻌﻤﻠﻴﺔ اﻟﻤﻨﺎﺳﺒﺔ ﻟﻠﺘﺠﺮﺑﺔ ﻻﻋﻄﺎء أﻓﻀﻞ اﻟﻨﺘﺎﺋﺞ وﺗﻢ .ﺳﺎﻋﺔ دون ﺗﻐﻴﻴﺮ
ﺻﻼﺣﻴﺔ اﻟﻄﺮﻳﻘِﺔ اﻟُﻤﻘَﺘَﺮﺣِﺔ إﺧﺘﺒﺮْت ﺑَﺘﺤﻠﻴﻞ ﻋﻴﻨﺎِت . ادﺧﺎﻟﻬﺎ ﻓﻲ ﻃﺮﻳﻘﺔ اﻟﺘﺤﻀﻴﺮ
 ﺗﺤﺖ اﻟﻈﺮوف اﻟﻤﺨﺘﺒﺮﻳﺔ اﻟﻤﺜﻠِﻰ ،ﺣﻴﺚ وﺟﺪ أن  ﻗﺎﻧﻮن ﺑﻴﺮ  واﻟﺴﻴﻔﺎدروآﺴﻴﻞاﻟﺘﻮﺑﺮاﻣﻴﺴﻴﻦ
 5 -01x9.6 -5 - 01 x83.1و5 -01 x41 -5 -01 x8.2يﻳﺘﻤﺎﺷﻲ ﻋﻠﻰ ﻣﺪى اﻟﺘﺮآﻴﺰ اﻟﻤﻮﻻر
= ﻣﻌﺎﻣﻞ اﻻرﺗﺒﺎط) اﻟﺘﺤﻠﻴُﻞ اﻹﻧﺤﺪاري ﻟﻤﻨﺤﻨﻲ ﺑﻴﺮ أﻇﻬﺮ ﻋﻼﻗﺔ ﺧﻄﻴﺔ .ﻋﻠﻰ اﻟﺘﻮاﻟﻰ
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، ووﺟﺪ أن أﻗﻞ آﻤﻴﺔ  ﻟﻠﺴﻴﻔﺎدروآﺴﻴﻞ(1999.0= ﻣﻌﺎﻣﻞ اﻻرﺗﺒﺎط)ﻟﻠﺘﻮﺑﺮاﻣﻴﺴﻴﻦ و(899.06
ﻣﺎﻳﻜﺮوﺟﺮاﻣﺎت 80.5 )M 60-01 X 9.8 ﻣﻦ اﻟﻤﺮآﺐ ﻳﻤﻜﻦ اﻟﻜﺸﻒ ﻋﻨﻬﺎ ﺑﻬﺬﻩ اﻟﻄﺮﻳﻘﻪ هﻲ 
 ﻋﻠﻰ ( ﻣﺎﻳﻜﺮوﺟﺮاﻣﺎت ﻓﻲ اﻟﻤﻠﻴﻠﺘﺮ اﻟﻮاﺣﺪM60-01 X 9.1 )396.0و( ﻓﻰ اﻟﻤﻠﻴﻠﺘﺮ اﻟﻮاﺣﺪ
 ﺗﻢ اﻟﺘﺄآﺪ ﻣﻦ دّﻗﺔ اﻟﻄﺮﻳﻘِﺔ ﺑﺘﺤﻠﻴﻞ ﺛﻼﺛﺔ ﻋﻴﻨﺎت ﻣﺨﺘﻠﻔِﺔ اﻟﺘﺮاآﻴﺰاﻟﺘﻮﺑﺮاﻣﻴﺴﻴﻦ.اﻟﺘﻮاﻟﻰ
وَت ﺑﻴْﻦ ﻣﻨﺨﻔﺾ و ﻳَﺘﻔﺎ(  إم) ﺣﻴﺚ أﻇﻬﺮت اﻟَﻨﺘﺎِﺋَﺞ ﺑﺄّﻧﺎﻹﻧﺤﺮاف اﻟﻤﻌﻴﺎريواﻟﺴﻴﻔﺎدروآﺴﻴﻞ
 x51.1 و ﻣﻮﻻري5-01 x9.11و 5-01 x56.ﻟﻠﺘﺮآﻴﺰﻓﻲ اﻟﻤﺪى ﺑﻴﻦ3 -01 x5و 3-01 x3.2
 ﻣﻮﻻري ﻋﻠﻰ 5- 01 x 25.5و 5-01 x57.2 ﻟﻠﺘﺮآﻴﺰﻓﻲ اﻟﻤﺪى ﺑﻴﻦ3-01 x8.5- 3-01
  .اﻟﺘﻮاﻟﻰ
اﺳﺘﺨﺪﻣﺖ اﻟﻄﺮﻳﻘﺔ اﻟﻤﺴﺘﺤﺪﺛﺔ ﺑﻨﺠﺎح ﻟﺘﺤﺪﻳﺪ آﻤﻴﺔ اﻟﺘﻮﺑﺮاﻣﻴﺴﻴﻦ ﻓﻲ ﻋﻴﻨﺎت ﺗﺠﺎرﻳﺔ 
ﻟﻠﻘﻄﺮ اﻟﻌﻴﻨﻴﺔ آﺎﻧﺖ   و ﺑﺎﻟﻨﺴﺒﺔ %95.0±5.99 اﻟﻤﺤﺘﻮي اﻟﻜﻤﻲ ﻣﻦ اﻟﺤﻘﻦ و آﺎﻧﺖ ﻧﺘﻴﺠﺔ
اﺳﺘﺨﺪﻣﺖ و. ﻟﻠﺘﻮﺑﺮادﻳﻜﺲ واﻟﺘﻮﺑﺮآﺲ ﻋﻠﻰ اﻟﺘﻮاﻟﻰ%83.0±1.29 و %35.0±5.05
اﻟﻄﺮﻳﻘﺔ اﻟﻤﺴﺘﺤﺪﺛﺔ ﺑﻨﺠﺎح ﻟﺘﺤﺪﻳﺪ آﻤﻴﺔ اﻟﺴﻴﻔﺎدروآﺴﻴﻞ ﻓﻲ ﻋﻴﻨﺎت ﺗﺠﺎرﻳﺔ ﻣﻦ اﻟﻜﺒﺴﻮﻻت و 
 ، ® اﻟﺘﺠﺎرﻳﺔ ﻣﻴﺪروآﺴﻴﻞﻟﻠﻜﺒﺴﻮﻻت ﺑﺎﻟﻨﺴﺒﺔ %51.1±6.99آﺎﻧﺖ ﻧﺘﻴﺠﺔ اﻟﻤﺤﺘﻮي اﻟﻜﻤﻲ
 اﻟﻤﺤﺘﻮي اﻟﻜﻤﻲ (.ﻟﻮﻧﺠﺴﻴﻒ )%52.0±31.101 و ( ®اﺑﻴﺪروآﺴﻴﻞ ) %80.1±7.201
  132.0± %73.99ﻟﻸﻗﺮاِص اﻟﺘﺠﺎرﻳِﺔ َآﺎن 
  :اﻟﺨﻼﺻﺔ
وﺟﺪ  آﻤﺎ .اﻟَﻨﺘﺎِﺋﺞ اﻟﻤﺘﺤﺼﻞ ﻋﻠﻴﻬﺎ ﻣﻊ دﻗﺔ%95.0±5.99  وﺟﺪ ان اﻟﻤﺤﺘﻮى اﻟﻜﻤﻰ ﻟﻠﺤﻘﻦ
، 6.99±51.1%ﺔ ﻣﻴﺪروآﺴﻴﻞ ان ﻧﺘﻴﺠﺔ اﻟﻤﺤﺘﻮى اﻟﻜﻤﻰ ﻟﻠﻜﺒﺴﻮﻻت اﻟﺘﺠﺎرﻳ
 .   ﻟﻮﻧﺠﺴﻴﻒ31.101±52.0% اﺑﻴﺪروآﺴﻴﻞ و 7.201±80.1%
اﻟَﻨﺘﺎِﺋﺞ اﻟﻤﺘﺤﺼﻞ ﻋﻠﻴﻬﺎ َآﺎﻧْﺖ دﻗﻴﻘﺔوﺗﻌﻄﻲ ﻧﻔﺲ اﻟﻨﺘﻴﺠﺔ ﻣﻘﺎرﻧﺔ ﺑﺎﻟﻄﺮﻳﻘِﺔ اﻟﺮﺳﻤﻴِﺔ 
آﻤﺎ أن اﻟﻄﺮﻳﻘﺔ اﻧﺘﻘﺎﺋﻴﻪ ﻟﻠﻌﻘﺎر وﻳﻤﻜﻦ أﺳﺘﺨﺪاﻣﻬﺎ ﻓﻰ وﺟﻮد ﻋﻨﺎﺻﺮ أﺧﺮى دون . اﻟﻤﺘﺒﻌﺔ
  اﻟﺤﻮﺟﺔ اﻟﻰ ﻓﺼﻠﻬﺎ
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1.INTRODUCTION 
1.1. Overview:- 
   Many of the organisms are classified as either Gram-positive or Gram-
negative. This classification is based on whether the organisms do or do 
not stain with Gram's stain, but it has a significance far beyond that of an 
empirical staining reaction. Gram-positive and Gram-negative organisms 
are different in several respects, not least in the structure of the cell wall, 
which has implications for the action of antibiotics.  
The cell wall of Gram-positive organisms is a relatively simple structure, 
15-50 nm thick. It consists of about 50% peptidoglycan, about 40-45% 
acidic polymer (which results in the cell surface being highly polar and 
carrying a negative charge) and about 5-10% proteins and 
polysaccharides. The strongly polar polymer layer influences the 
penetration of ionized molecules and favours the penetration of positively 
charged compounds, such as streptomycin, into the cell. 
 The cell wall of Gram-negative organisms is much more complex due to 
the complex polysaccharides in the outer surface, the reason why some 
antibiotics are less active against Gram-negative than Gram-positive 
bacteria. This is the basis of the extraordinary insusceptibility to most 
antibiotics. (Rang et al, 2005). 
  Antimicrobial drugs are effective in the treatment of infections because 
of their selective toxicity--the ability to kill an invading microorganism 
without harming the cells of the host. A number of antibiotics exert their 
antimicrobial effect by targeting bacterial ribosome, which has 
components that differ structurally from those of the mammalian 
cytoplasmic ribosome. The bacterial ribosome is smaller (70s) than the 
mammalian ribosome (80s) and is composed of 50s and 30s subunits as 
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compared to 60s and 40s subunits.  
-:escosidyAminogl. .21
    Aminoglycosides are a group of  bactericidal antibiotics originally 
obtained from various streptomyces species and sharing chemical, 
antimicrobial, pharmacological, and toxic characteristics. 
The group includes streptomycin, neomycin, kanamycin, amikacin, 
gentamicin, tobramycin,sisomicin, netilmicin, and others. 
Aminoglycosides are used most widely against gram-negative enteric 
bacteria, especially in bacteremia and sepsis, in combination with 
vancomycin or a penicillin for endocarditis, and for treatment of 
tuberculosis. Streptomycin is the oldest and best-studied of the 
aminoglycosides. 
Gentamicin, tobramycin, and amikacin are the most widely employed 
aminoglycosides at present.                                                                     
Neomycin and kanamycin are now largely limited to topical or oral use.   
(Bertram G. Katzung ,2005).                                                                                    
1.2.1. Nomeclature:-                                                                                                  
    Aminoglycosides that are derived from bacteria of the Streptomyces 
genus are named with the suffix -mycin, while those which are derived 
from Micromonospora are named with the suffix -micin. This 
nomenclature system is not specific for aminoglycosides. For example 
vancomycin is a glycopeptide antibiotic and erythromycin, which is 
produced from a defunct species of Streptomyces along with its synthetic 
derivatives clarithromycin and azithromycin are macrolides - all of which 
differ in their mechanism of actions. 
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1.2.2. Structural Physical and Chemical Properties:- 
     Aminoglycosides have a hexose ring, either streptidine (in streptomycin) 
or 2-deoxystreptamine (other aminoglycosides), to which various amino 
sugars are attached by glycosidic linkages(Figures 1–1 and 1–2). They are 
water-soluble, stable in solution, and more active at alkaline than at acid pH. 
Aminoglycosides frequently exhibit synergism with -lactams or vancomycin 
in vitro. 
In combination they eradicate organisms more rapidly than would be 
predicted from the activity of either single agent. However, at high 
concentrations aminoglycosides may complex with –lactam drugs, resulting 
in loss of activity, and they should not be mixed together for administration. 
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Figure 1–1. Structure of streptomycin. 
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Figure 1–2. 
 Structures of several important aminoglycoside antibiotics. Ring II is 2-
deoxystreptamine. The resemblance between kanamycin and amikacin and 
between gentamicin, netilmicin, and tobramycin can be seen. The circled 
numerals on the kanamycin molecule indicate points of attack of plasmid 
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mediated bacterial transferase enzymes. 
1.2.3. Mechanism of action  
    Aminoglycosides inhibit bacterial protein synthesis. Protein synthesis takes 
place in the ribosomes-cytoplasmic nucleoprotein structures. Ribosomes are 
different in eukaryotes and prokaryotes. The bacterial ribosome consists of a 
50s subunit and 30s subunit whereas in the mammalian ribosome the subunits 
are 60s and 40s. The other elements involved in peptide synthesis are 
messenger RNA (mRNA), which forms the template for protein synthesis, 
and transfer RNA (tRNA), which brings the individual amino acids to the 
ribosome. The ribosome has three binding sites for tRNA, the A,P and E sites.
   mRNA, which is transcribed from DNA, becomes attached to the 30s 
subunit of the ribosome. 
   The 50s subunit then binds to 30s subunit to form 70s subunit, which moves 
along the mRNA so the successive codons ( a triplet consisting of three 
nucleotides that codes for a specific amino acid.) of the messenger along the 
ribosome from A position to the P position. 
   Aminoglycosides work by binding to the bacterial 30s ribosomal subunit 
(some work by binding to the 50s subunit), inhibiting the translocation of the 
peptidyl-tRNA from the A-site to the P-site and also causing misreading of 
mRNA, leaving the bacterium unable to synthesize proteins vital to its 
growth. (Figure 1-3).  (Rang et al,2005).    
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Figure 1-3: Schematic diagram of bacterial synthesis indicating the 
points at which antibiotics inhibit the process 
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      Their penetration through the cell membrane of the bacterium depends 
partly on oxygen-dependent active transport by a polyamine carrier system 
and they have minimal action against anaerobic organisms. The effect of the 
aminoglycosides is bactericidal and is enhanced by agents that interfere with 
cell wall synthesis (Rang et al,2005). 
1.2.4. Resistance:- 
 
   Resistance to aminoglycosides is becoming a problem. It occurs by several 
different mechanisms, the most important being inactivation by microbial 
enzymes of which there are nine or more. Amikacin was designed as a poor 
substrate for these enzymes; but some organisms have developed enzymes 
that inactivate this agent as well 
(www.rxlist.com/cgi/generic/tobramycin.htm, 5/2009).  
  
 -: Tobramycin5.2.1 
    -:Definition. .1.5.21
  Tobramycin is an aminoglycoside antibiotic used to treat various types of 
bacterial infections, particularly Gram-negative infections. Its systemic 
(IUPAC) name is 4-amino-2-[4,6-diamino-3- [3-amino-6-(aminomethyl) -5-
hydroxy-tetrahydropyran-2-yl]oxy- 2-hydroxy-cyclohexoxy]-6-
(hydroxymethyl) tetrahydropyran-3,5-diol. It has the molecular formula (C18 
H37N5O9). 
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  -:Physical properties. .2.5.21
Tobramycin (M.wt 467) is a white or almost white powder, freely soluble in 
water, very slightly soluble in alcohol, practically insoluble in ether. 
(B.P.2000)                                                                                                            
-:Mechanism of action. .3.5.21
Tobramycin works by binding the bacterial 30s and 50s ribosomal subunit, 
preventing formation of the 70s complex. As a result, mRNA cannot be 
translated into protein and cell death ensues. (as in Figure 1-3).
 -:Pharmacological action. .4.5.21
Tobramycin is indicated for the treatment of serious bacterial infections 
caused by susceptible strains of the designated microorganisms in the diseases 
listed below:  
Septicemia in the pediatric patient and adult caused by. P. aeruginosa, E. coli, 
and Klebsiella spp.                                                                                                
Lower respiratory tract infections caused by P.aeruginosa, Klebsiella spp, 
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Enterobacter spp, Serratia spp, E.coli, and S.aureus (penicillinase and non-
penicillinase producing strains).                                                                           
Serious central-nervous-system infections (meningitis) caused by susceptible 
organisms .                                                                                                           
Intra-abdominal infections, including peritonitis, caused by E. coli, Klebsiella 
spp, and Enterobacter spp.                                                                                    
Skin, bone, and skin structure infections caused by P.aeruginosa, Proteus spp, 
E. coli, Klebsiella spp, Enterobacter spp, and S.aureus.                                      
Complicated and recurrent urinary tract infections caused by P.aeruginosa, 
Proteus spp (indole-positive and indole-negative),E. coli, Klebsiella spp, 
Enterobacter spp, Serratia spp, S.aureus, Providencia spp, and Citrobacter 
spp.                                                                                                  
Aminoglycosides, including tobramycin, are not indicated in uncomplicated 
initial episodes of urinary tract infections unless the causative organisms are 
not susceptible to antibiotics having less potential toxicity. Tobramycin may 
be considered in serious staphylococcal infections when penicillin or other 
potentially less toxic drugs are contraindicated and when bacterial 
susceptibility testing and clinical judgment indicate its use.  
( www.rxlist.com/cgi/generic/tobramycin.htm,5/2009) 
 -:Pharmacokinetics and metabolism..5.5.21
Tobramycin is rapidly absorbed following intramuscular administration. Peak 
serum concentrations of tobramycin occur between 30 and 90 minutes after 
intramuscular administration. Following an intramuscular dose of 1 mg/kg of 
body weight, maximum serum concentrations reach about 4 µg/mL, and 
measurable levels persist for as long as 8 hours. Therapeutic serum levels are 
generally considered to range from 4 to 6 µg/mL. When tobramycin is 
administered by intravenous infusion over a 1-hour period, the serum 
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concentrations are similar to those obtained by intramuscular administration. 
Tobramycin is poorly absorbed from the gastrointestinal tract.                           
In patients with normal renal function, except neonates, tobramycin 
administered every 8 hours does not accumulate in the serum. However, in 
those patients with reduced renal function and in neonates, the serum 
concentration of the antibiotic is usually higher and can be measured for 
longer periods of time than in normal adults. Dosage for such patients must, 
therefore, be adjusted accordingly.                                                       
Following parenteral administration, little, if any, metabolic transformation 
occurs, and tobramycin is eliminated almost exclusively by glomerular 
filtration. Renal clearance is similar to that of endogenous creatinine. 
Ultrafiltration studies demonstrate that practically no serum protein binding 
occurs. In patients with normal renal function, up to 84% of the dose is 
recoverable from the urine in 8 hours and up to 93% in 24 hours.                      
Peak urine concentrations ranging from 75 to 100 µg/mL have been observed 
following the intramuscular injection of a single dose of 1 mg/kg. After 
several days of treatment, the amount of tobramycin excreted in the urine 
approaches the daily dose administered. When renal function is impaired, 
excretion of tobramycin is slowed, and accumulation of the drug may cause 
toxic blood levels.                                                                                          
The serum half-life in normal individuals is 2 hours. An inverse relationship 
exists between serum half-life and creatinine clearance, and the dosage 
schedule should be adjusted according to the degree of renal impairment. In 
patients undergoing dialysis, 25% to 70% of the administered dose may be 
removed, depending on the duration and type of dialysis.                                   
Tobramycin can be detected in tissues and body fluids after parenteral 
administration. Concentrations in bile and stools ordinarily have been low, 
which suggests minimum biliary excretion. Tobramycin has appeared in low 
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concentration in the cerebrospinal fluid following parenteral administration, 
and concentrations are dependent on dose, rate of penetration, and degree of 
meningeal inflammation. It has also been found in sputum, peritoneal fluid, 
synovial fluid, and abscess fluids, and it crosses the placental membranes. 
Concentrations in the renal cortex are several times higher than the usual 
serum levels. Probenecid does not affect the renal tubular transport of 
tobramycin. ( www.rxlist.com/cgi/generic/tobramycin.htm,5/2009) 
-:Adverse effects. .6.5,21
Like other aminoglycosides, tobramycin can cause deafness or a loss of 
equilibrioception (vertigo) in genetically susceptible individuals. These 
individuals have a normally harmless mutation in their DNA, that allows the 
tobramycin to affect their cells. The cells of the ear are particularly sensitive 
to this. Tobramycin can also be highly toxic to the kidneys (nephrotoxicity), 
particularly if multiple doses accumulate over a course of treatment.                 
For these reasons, when tobramycin is given parenterally, it is usually dosed 
by body weight. Various formulae exist for calculating tobramycin dosage. 
Also serum levels of tobramycin are monitored during treatment. Other 
reported adverse reactions possibly related to tobramycin include anemia, 
granulocytopenia, and thrombocytopenia; and fever, rash, exfoliative 
dermatitis, itching, urticaria, nausea, vomiting, diarrhea, headache, lethargy, 
pain at the injection site, mental confusion, and disorientation.  
(www.rxlist.com/cgi/generic/tobramycin.htm,5/2009) 
-:Available dosage forms. .7.5.21
Tobramycin is available as: 
- Tobramycin for Injection: 20mg/ml, 40mg/ml and 80mg/2ml. 
- Inhalation solution: 5 mL ampule contains 300 mg tobramycin and 
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11.25 mg sodium chloride in sterile water for injection. 
- Ophthalmic suspension: Tobramycin 0.3% (3 mg/ml) and 
Dexamethasone 0.1% (1 mg/ml). 
- Ophthalmic eye drops: tobramycin 0.3%(3mg/ml).  
- Ophthalmic eye drops: tobramycin 0.3% (3mg/ml) and dexamethasone 
0.1% (1 mg/ml).  
1.2.5.8.Examples of methods used for quantitative analysis of
tobramycin:- 
Some methods used for the assay of tobramyin in bulk, and pharmaceutical
forms or biological fluids reviewed from the literature include: 
1. A simple and selective micellar electrokinetic chromatography (MEKC) 
with UV detection is described for simultaneous determination of tobramycin, 
performed in Tris buffer (180 mM; pH 9.1) with 300 mM sodium 
pentanesulfonate (SPS) as an anionic surfactant. Under this condition, good 
separation with high efficiency and the required short analysis time is 
achieved. The linear range of the method for the determination of tobramycin, 
was 0.4-2.0 mg / mL; the detection limit (signal-to-noise ratio = 3; injection, 
0.5 psi 5 s) was 0.2mg / mL. The small amount of sample required and the 
expeditiousness of the procedure allow content uniformity to be determined in 
individual commercial products. (Yeh HH, Lin SJ, Ko JY, Chou CA, Chen 
SH,2005). 
2. A spectrophotometric assay method for the quantitative 
determination of amikacin, kanamycin, neomycin, and tobramycin in 
pharmaceutical dosage forms has been developed. The method is based 
on the Hantzsch reaction, forming dihydrolutidine derivatives which 
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can be measured spectrophotometrically. The excipients EDTA, phenol, 
sodium bisulfite, and sodium citrate do not interfere, while salts of 
ammonia do interfere. The relative standard deviations based on seven 
readings were 1.64, 1.88, 2.10, and 1.93% for amikacin, kanamycin, 
neomycin, and tobramycin, respectively. Assay results have been 
compared with microbiological assay results provided by the 
manufacturers. The assay method appears to be stability indicating. (V. 
Das Gupta , Kenneth R. Stewart , James M. Gunter ,2006) 
3. In a weak acidic medium, the reaction of some aminoglycoside 
antibiotics (AGs) such as kanamycin sulfate (KANA), gentamycin 
sulfate (GEN), and tobramycin sulfate (TOB) with acid thiazolyl bisazo 
dye Titan Yellow (TY) can result in the fading of TY. The maximum 
fading wavelength was located at 409 nm. The molar absorptivities 
(ɛ /×104 1 mol−1 cm−1) were 2.0, 1.5 and 2.5 for KANA, GEN and TOB, 
respectively. The spectral characteristics, effect factors, optimum 
conditions of the reaction and the influence of foreign substances were 
also investigated. The procedure is easy and fast. This method has high 
sensitivity and can be applied to the determination of commercial 
aminoglycoside antibiotics and serum samples with satisfactory results. 
(Wang Mingxia , Liu Zhongfang , Hu Xiaoli , Liu Shaopu and 
Kong Ling,2005). 
4. A spectrophotometric method for determination of neomycin, 
kanamycin, tobramycin and amikacin is proposed, based on the Rimini 
test with disodium pentacyanonitrosylferrate(II) for primary and 
secondary aliphatic amines. The absorbance of the coloured addition 
product is measured. Beer's law is valid over a wide concentration 
range. The method is relatively fast and can be used in control of the 
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manufacture of the antibiotics and their purity, instead of the much 
slower microbiological method. It is also applicable for determination 
of these antibiotics in formulations.( Maya Confino and 
Panayot Bontchev ,1990) 
5. A sensitive and accurate spectrophotometric method for the 
quantitative determination of tobramycin in either pure form or in 
injections is proposed. The method is based on the development of a 
green coloured product with 3- methyl-2-benzothiazolinone hydrazone 
hydrochloride and ferric chloride having an absorption maximum at 
645nm. Beer's law is obeyed in the concentration range of 50-500 
miu/ml. The optimum reaction conditions and other analytical 
parameters are statistically evaluated. (C Srinivasulu, G Vidyasagar, 
BS Sastry,2009) 
6. A simple, fast and reliable procedure for the determination of seven 
major aminoglycosides in commercial formulations (injections, 
capsules, eye drops, solutions and ointments) is presented. The 
aminoglycosides are separated on silica gel plates then located with 
ninhydrin and analysed in situ using a chromatogram 
spectrophotometer. Linearity tests, repeatability (relative standard 
deviation 3.5%) detection limits (60–200 ng) were satisfactory for all 
the compounds. Recovery data in pharmaceutical formulations 
(expressed as the percentage of the label claim) from thin-layer 
chromatography (TLC) and microbiological assays did not give any 
significant difference (P = 0.05); this result shows that TLC is a 
reliable method for the determination of aminoglycosides as the drug 
substance and in pharmaceutical formulations. (M. Sekkat, H. Fabre, 
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M. Simeon de Buochberg and B. Mandrou, 1989). 
7. A Spectrophotometric method for determination of the 
aminoglycoside antibiotics tobramycin, apramycin and kanamycin in 
formulations has been developed. The method is based on the 
formation in slightly acidic medium of an ion-pair between the 
protonated antibiotic and the anionic form of Bromothymol Blue. The 
ion-pair is extracted with chloroform and the absorbance measured at 
430 nm. Beer's law is followed in the range 1–5×10–3 M. 
(P. R. Bontchev, P. Papazova , M. Confino and D. Dimova,1984) 
8. Tobramycin and its major impurities, including kanamycin B and 
neamine (neomycin A), can be separated on a strong anion-exchange 
column using a weak potassium hydroxide eluent (2.00 mM) at a 
column temperature of 30 degrees C, and directly detected by 
integrated pulsed amperometric detection (IPAD). The resolution 
(United States Pharmacopeia (USP) definition) between tobramycin 
and kanamycin B ranged from 5.71 and 6.06 over 7 days of 
consecutive analysis (5.92+/-0.07, n = 590 injections). Due to the 
difficulty of producing weak hydroxide eluents of the required purity 
(i.e. carbonate-free), this method depends on automatic eluent 
generation to ensure method ruggedness. This method exhibited good 
long-term (50 days, 2368 injections) retention time stability with 
R.S.D.s of 0.4% and 0.3% for tobramycin and kanamycin B, 
respectively. Peak area R.S.D.s for tobramycin and kanamycin B (10 
microM each, 20 microL injection) over 7 days (572 injections) were 
2.3% and 1.9%, respectively. Method robustness was evaluated by 
intentionally varying the flow rate, eluent concentration, column 
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temperature, and column. Based on the results of these evaluations, this 
method can be used for tobramycin identity, assay, and purity (Hanko 
VP, Rohrer JS, 2006). 
9. Simple and sensitive spectrophotometric methods for the 
determination of Tobramycin sulphate were described. Method A was 
based on the formation of blue colour complex when drug solution 
reacts with MBTH (3-methyl 2 Benzothiazoline hydrazone 
hydrochloride) in the presence of Sodium periodate and acetic acid the 
coloured complex has a Amax at 660nm. Method B was based on 
formation on green colour complex, when the drug solution reacts with 
potassium permanganate in the presence of sodium hydroxide. The 
coloured complex has a max at 425 nm. Beer's law was obeyed in the 
concentration range of 10 miu g -800 miu g/ml (Sagar V et al,2003). 
10. To evaluate the release kinetics, in a simulated body fluid, of 
tobramycin (TOB) from carbonated apatite (CHA) in the form of 
granulate, a sensitive and reliable liquid chromatographic method was 
developed. Chromatographic separation was performed on a Metrosep 
Carb 1 anionic column by using 0.1 M NaOH as mobile phase at a flow 
rate of 1.0 ml min− 1. TOB was quantified by pulsed amperometric 
detection using a 3-potential waveform on Au electrode. A linear 
relationship for TOB was found in the range 0.17–2.50 mg l− 1 with a 
LOD of 0.05 mg l− 1. The method exhibited good retention time and 
peak area reproducibility (Federica Valentini, Pier Luigi Buldini, Elena 
Landi, Anna Tampieri and Domenica Tonelli, 2008) 
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1.3. Cephalosporin's:-  
1.3.1. Chemistry:- 
The nucleus of the cephalosporin's, 7-aminocephalosporanic acid (Figure 1-
1), bears a close resemblance to 6-aminopenicillanic acid. The intrinsic 
antimicrobial activity of natural cephalosporins is low, but the attachment of 
various R1 and R2 groups has yielded drugs of good therapeutic activity and 
low toxicity (Figure 1–4). The cephalosporin's have molecular weights of 
400–450. They are soluble in water and relatively stable to pH and 
temperature changes. Cephalosporin's can be classified into four major groups
or generations, depending mainly on the spectrum of antimicrobial activity. 
As a general rule, first-generation compounds have better activity against 
gram-positive organisms and the later compounds exhibit improved activity 
against gram-negative aerobic organisms. (Bertram G. Katzug, 2005) 
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Figure 1-4 Nucles of cephalosporines structure,and classification of 
cephalosporines  
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1.3.2.Cefadroxil:-                                                                                            
1.3.2.1.Definition:- 
    Cefadroxil is a broad-spectrum antibiotic effective in Gram-positive and 
Gram-negative bacterial infections. It is a bactericidal antibiotic. It is 
chemically designated as 5-Thia-l-azabicyclo[4.2.0]oct-2-ene-2-carboxylic 
acid, 7-[[amino(4-hydroxyphenyl)acetyl]amino]-3-methyl-8-oxo-, 
monohydrate.. It has the following structural formula: 
          
 1.3.2.2. Physical properties:- 
    It is a white to yellowish-white crystalline powder. It is soluble in water 
and it is acid- stable. It has the formula C16H17N3O5S•H20 and the molecular 
weight of 381.40            
1.3.2.3.Mechanism of action:- 
       Cefadroxil, like all -lactam antibiotics, inhibit bacterial growth by 
interfering with a specific step in bacterial cell wall synthesis. The cell wall is 
a rigid outer layer that is not found in animal cells. It completely surrounds 
the cytoplasmic membrane , maintaining the shape of the cell and preventing 
cell lysis- from high osmotic pressure. The cell wall is composed of a 
complex cross linked polymer, peptidoglycan (murein,mucopeptide), 
consisting of polysaccharides and polypeptides. The polysaccharide contains 
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alternating amino sugars, N-acetylglucosamine and N-acetylmuramic acid. A 
five-amino-acid peptide is linked to the N-acetylmuramic acid sugar. This 
peptide terminates in D-alanyl-D-alanine. Penicillin-binding proteins (PBPs) 
catalyze the trans peptidase reaction that removes the terminal alanine to form 
a crosslink with a nearby peptide, which gives cell wall its structural rigidity.  
β-lactam antibiotics are structural analogs of the natural D-Ala-D-Ala 
substrate and they are covalently bound by PBPs at the active site. After a β –
lactam antibiotic become attached to the PBP, the trans peptidation reaction is 
inhibited, peptidoglycan synthesis is blocked, and the cell dies. The exact 
mechanism responsible for cell death is not completely understood, but 
autolysins, bacterial enzymes that remodel and break down cell wall, are 
involved. Penicillins and cephalosporins are bactericidal only if cells are 
actively growing and synthesizing cell wall. (Bertram G. Katzug,2005.) 
 
1.3.2.4. Clinical Uses:- 
    Cefadroxil is indicated for the treatment of patients with infections caused 
by susceptible strains of the designated organisms in the following diseases: 
Urinary tract infections caused by E. coli; P. mirabilis, and Klebsiella 
species.                                                                                                              
Skin and skin structure infections caused by staphylococci and/or 
streptococci.                                                                                                  
Pharyngitis and/or tonsillitis caused by Streptococcus pyogenes (Group A 
beta-hemolytic streptococci). 
1.3.2.5.Pharmacokinetics:- 
Cefadroxil is almost completely absorbed from the gastrointestinal tract. After 
doses of 500 mg and 1 g by mouth, peak plasma concentrations of about 16 
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and 30 micrograms/mL respectively are obtained after 1.5 to 2 hours. 
Although peak concentrations are similar to those of cefalexin, plasma 
concentrations are more sustained. Dosage with food does not appear to affect 
the absorption of cefadroxil. About 20% of cefadroxil is reported to be bound 
to plasma proteins. The plasma half-life of cefadroxil is about 1.5 hours and is 
prolonged in patients with renal impairment. 
Cefadroxil is widely distributed to body tissues and fluids. It crosses the 
placenta and appears in breast milk. 
More than 90% of a dose of cefadroxil may be excreted unchanged in the 
urine within 24 hours by glomerular filtration and tubular secretion; peak 
urinary concentrations of 1.8 mg/mL have been reported after a dose of 500 
mg. Cefadroxil is removed by haemodialysis. 
1.3.2.6. Side effects:- 
     The most common side effects of Cefadroxil are diarrhea (which, less 
commonly, may be bloody), nausea, upset stomach, and vomiting. Other side 
effects include:                                                                                              
Rashes ,hives itching ,red, swollen, or blistered skin, unusual bruising or 
bleeding, sore throat, difficulty breathing, tightness in the chest, swelling of 
the mouth, face, lips, or tongue ,decreased urination ,dark urine, vaginal 
itching, odor, or discharge, fever ,chills, joint pain, seizures, cramps, unusual 
tiredness or weakness, yellowing of the skin or eyes. 
1.3.2.7. Available Dosage Forms:- 
Cefadroxil is available as 
1. Capsules. 250 mg - 500 mg. 
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2. Oral suspension 125 mg/5ml-250/5ml. 
1.3.2.8. Chemistry of cefadroxil:- 
i. Ultraviolet spectrum:- 
 
1.3.2.9. Examples of methods used for quantitative analysis of cefadroxil:-
Some methods used for the assay of cefadroxil in bulk, and pharmaceutical 
forms or biological fluids reviewed from the literature include 
1. Three simple, rapid and sensitive spectrophotometric procedures were 
developed for the analysis of cephapirin sodium, cefazoline sodium, 
cephalexin monohydrate, cefadroxil monohydrate , cefotaxime sodium, 
cefoperazone sodium and ceftazidime pentahydrate in pure form as 
well as in their pharmaceutical formulations. The methods are based on 
the reaction of these drugs as n-electron donors with the σ-acceptor 
iodine, and the π-acceptors: 2,3-dichloro-5,6-dicyano-p-benzo-quinone 
(DDQ) and 7,7,8,8-tetracyanoquinodimethane (TCNQ). Depending on 
the solvent polarity, different coloured charge-transfer complexes and 
radicals were developed. Different variables and parameters affecting 
the reactions were studied and optimized. The obtained charge-transfer 
complexes were measured at 364 nm for iodine (in 1,2-dichloroethane), 
460 nm for DDQ (in methanol) and 843 nm for TCNQ (in acetonitrile). 
Beer's plots were obeyed in a general concentration range of 6–50, 40–
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300 and 4–24 µg ml−1 with iodine, DDQ and TCNQ, respectively, with 
correlation coefficients not less than 0.9989. (Gamal A. Saleh, Hassan 
F. Askal , Mohamed F. Radwan and Mahmoud A. Omar,2001). 
2. A chemiluminescent method using flow injection is described for the 
determination of cefadroxil monohydrate. The method is based on the 
chemiluminescence reaction of cefadroxil with potassium 
permanganate in sulphuric acid, sensitized by quinine. The proposed 
procedure allows the determination of cefadroxil over the concentration 
range 0.1–30 µg ml−1 with a detection limit of 0.05 µg ml−1 and a 
sample measurement frequency of 150 samples h−1. The method was 
successfully applied to the determination of cefadroxil in 
pharmaceutical preparations and biological fluids (Fatma A. Aly, 
Nawal A. Alarfaffj and Abdulrahman A. Alwarthan,1998). 
3. Two simple, rapid and selective spectrophotometric procedures were 
developed for the determination of amoxicillin and cefadroxil. The 
methods are based on the selective oxidation of the drugs with N-
bromosuccinimide or N-chlorosuccinimide in an alkaline medium to 
give an intense yellow product ( max= 395 nm). The reaction conditions 
were studied and optimized. The reactions obey Beer's law over the 
range 1–20 µg ml–1 for the two drugs with the two reagents ( Gamal A. 
Saleh,1996). 
4. Three simple and sensitive visible spectrophotometric methods for the 
assay of cefadroxil have been developed. Method A (λmax, 410 nm) is 
based on the reaction of cefadroxil with 3-methyl-2-benzothiazolinone 
hydrazone hydrochloride in the presence of ceric ammonium sulphate. 
Method B (λmax, 510 nm) involves the reaction with 4-aminophenazone 
in the presence of potassium hexacyanoferrate(III). Method C (λmax, 
620nm) involves reaction with 2, 6-dichloroquinone-4-chlorimide 
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(Gibb's reagent). All variables have been optimised and the reaction 
mechanisms presented. Regression analysis of the Beer's plots showed 
good correlation in the concentration ranges 1.0-6.0, 2.0-24.0 and 1.0-
6.0 µg/ml for methods A, B and C, respectively (Sastry C. S. P. ; 
Kolliramarao ; Prasad D. S, 2003) . 
5. Two simple and selective spectrophotometric methods were developed 
for the quantitative determination of cefoperazone sodium, cefadroxil 
monohydrate, cefprozil anhydrous and amoxicillin trihydrate in pure 
forms as well as in their pharmaceutical formulations. The methods are 
based on the selective oxidation of these drugs with either Ce (IV) or 
Fe (III) in acid medium to give an intense yellow coloured product 
(λmax=397 nm). The reaction conditions were studied and optimized. 
Beer's plots were obeyed in a general concentration range of 5–30 µg 
ml−1 with correlation coefficients not less than 0.9979 for the four drugs 
with the two reagents (Hesham Salem and Gamal A. Saleh,2002). 
6. Four simple and selective spectrophotometric methods were developed 
for the quantitative determination of some phenolic β-lactam antibiotics 
(amoxicillin trihydrate, cefoperazone sodium, cefadroxil monohydrate, 
and cefprozil anhydrous) in pure forms as well as in their 
pharmaceutical formulations through their nitration and subsequent 
complexation with an nucleophilic reagent (method I), nitrosation and 
subsequent metal chelation (method II), coupling with diazo reagent 
(method III), and reaction with copper and extraction of the resulting 
chelate into chloroform (method IV). The reaction conditions were 
studied and optimized. Beer’s plots were obeyed in a general 
concentration range of 5–30 ug ml−1 with correlation coefficients not 
less than 0.9997 for the four drugs (Hesham Salem,2004) . 
7. The use of molybdophosphoric acid as an oxidising agent for the 
26 
 
spectrophotometric determination of four cephalosporin derivatives, 
viz., cefadroxil monohydrate (I), cefapirin sodium (II), ceforanide L-
lysine (III) and cefuroxime sodium (IV), either in the pure form or in 
pharmaceutical formulations is described. Beer's law is obeyed up to 
100 µg ml–1 for I, up to 60 µg ml–1 for II and IV and up to 80 µg ml–1 
for III. The molar absorptivities were 4.58 × 103, 11.3 × 103, 9.8 × 103 
and 10.9 × 103 l mol–1 cm–1 and the Sandell sensitivities were 83.3, 
39.3, 53.0 and 41.0 ng cm–2 for I, II, III and IV, respectively. The 
slopes and intercepts of the equations of the regression line were 
calculated for each of these drugs with the following correlation 
coefficients: I, 0.9993; II, 0.9999; III, 1.000; and IV, 0.9999. These 
antibiotics were determined successfully both in the pure form and in 
pharmaceutical preparations (Prodromos B. Issopoulos,1989). 
8. A sequential injection analysis (SIA) spectrophotometric procedure for 
cefadroxil determination has been developed. The SIA instrumentation 
was modified to achieve the desired function and operations by using 
the software developed to interface the PC with the conventional SIA 
system. The method is based on the measurement of a red, water-
soluble product formed by the reaction between cefadroxil and 4-
aminoantipyrine in the presence of alkaline potassium 
hexacyanoferrate(III) at 510 nm. Optimum conditions for determining 
the drug were investigated. Beer's law was obeyed over the 
concentration ranges of 1 - 10 mg L-1 and 10 - 50 mg L-1 with a 
detection limit (3 σ) of 0.17 mg L-1 and a limit of quantification (10 σ) 
of 0.56 mg L-1  (Jirayu Makchit et al, 2005). 
9. A new, simple, and sensitive kinetic spectrophotometric method is 
described for analysis of cefadroxil by measurement of its absorbance 
at 470 nm after hydrolysis with NaOH at 80°C. Studies of the method's 
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precision and accuracy gave a standard deviation of 0.44 µg/mL and a 
relative standard deviation of 1.93%. The method determines cefadroxil 
over the concentration range 10-100 µg/mL (Helaleh M. I. H. (1) ; ABU-
Nameh E. S. M.,2008). 
10. A simple and sensitive spectrophotometric method is described for the 
determination of some phenolic antibiotics namely: cefadroxil, 
amoxicillin and vancomycin. The method is based on the measurement 
of the orange yellow species produced when the drugs are coupled with 
diazotized benzocaine in triethylamine medium. The method is 
applicable over the range of 0.8–12µg/ml for cefadroxil, 2–16µg/ml 
for amoxicillin and 2–18µg/ml for vancomycin. The formed 
compounds absorb at 455nm for both cefadroxil and amoxicillin and 
at 442nm for vancomycin. The proposed method has detection limits 
of 0.018µg for cefadroxil, 0.0034µg for amoxicillin and 0.0156µg 
for vancomycin. (Saadia M. El-Ashry,2000). 
11. Hydrotropy is one of the reliable methods to enhance aqueous 
solubility of poorly soluble drugs. In the present investigation, 
hydrotropic solution of urea (6 M) was employed as a solubilizing 
agent to solubilize the poorly water-soluble drug, cefadroxil, in the 
tablet form and determined with the help of spectrophotometric 
determination in ultraviolet region. In solubility determination study, it 
was found that there was more than 10-fold enhancement in solubility 
of cefadroxil in 6-M urea solution. Cefadroxil showed maximum 
absorption at 263 nm and obeyed Beer's law in concentration range of 
10-80 µg/ml. Results of analysis were validated statistically and by 
recovery studies. The proposed method is new, simple, eco-friendly, 
economic, and accurate and can be utilized in routine analysis of 
cefadroxil tablets (Ravi S Shukla et al, 2008). 
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1.4.Spectrophotometry: 
The technique of ultraviolet-visible spectrophotometry is one of the most
commonly used techniques in pharmaceutical and biomedical analysis. It has
been employed in quantitative purposes and with certain limitations for 
characterization of drugs impurities, metabolites and related substances. 
The technique involves the measurement of the amount of ultraviolet (190-
380nm) or visible (380-800nm) radiation absorbed by a substance in solution.
Absorption of light in both the UV and visible region of the electromagnetic
spectrum occurs when the energy of the light matches the energy required to
induce an electronic transition and it is associated with vibrational and 
rotational transitions in the molecule. 
Spectral selectivity is induced and/or enhanced by a number of chemicals or
by instrumental technique such as difference, higher-derivative and dual 
wavelength spectrophotometry. 
Spectral interference can often arise from what is known as "irrelevant" 
nonspecific absorption, and from absorption by other materials and
impurities, which may be present. 
When interference is due to spectral overlap of two or more well- defined 
components, a number of methods are adopted to measure the individual
concentrations. These methods include the Vierodt multi-wavelength 
technique, least squares deconvolution and second or higher derivative
spectrophotometry (Anthony et al, 1986). 
1.5. Quantitative Spectrophotometric Assay of Medicinal Substances: 
The assay of absorbing substance can be carried out by making a solution of
the substance in a transparent solvent and measuring its absorbance at a
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suitable wavelength. The wavelength normally selected is a wavelength of
maximum absorption (λmax) where small errors in the settings of the
wavelength scale will have little effects on the measured absorbance. Ideally, 
the concentration should be adjusted to give an absorbance reading of
approximately between 0.4 - 0.9, around which the accuracy and precision of 
measurement are optimal. It is often preferred to read the absorbance from the
instrument display under non-scanning conditions, i.e. with the 
monochromator set at the analytical wavelength.  Alternatively, the
absorbance can be obtained by using a recording double beam
spectrophotometer (Anthony et al, 1986). 
The concentration of the absorbing substance can be calculated from the 
measured absorbance using one of three principal procedures. 
A.  Use of Standard Absorptivity Value Procedure: 
 British pharmacopoeia contains absorptivity values for stable substances. 
B.  Use of Calibration Graphs: 
In this procedure, the absorbances of a number of standard solutions (4-6) of 
reference substance at concentrations encompassing the sample concentration
are measured and a calibration curve of absorbance versus concentrations is
constructed. Concentration of analyte can be read from the resultant graph. 
C.  Single or Double Point Standardization: 
The single point procedure involves the measurement of absorbance of a
sample solution and solution of the reference substance; the standard and
sample solutions are prepared in a similar manner.  Final concentration of the
sample solution should be close to that of the standard solution. 
The concentration of the substance in the sample can be calculated from the
proportional relationship that exists between absorbance and concentration, 
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Beer’s law being obeyed for such range of concentrations. 
C test = A test x C std / A std 
C test is the concentration of test substance. 
A test is the absorbance of test substance. 
C std is the concentration of standard. 
A std is the absorbance of standard. 
Pharmacopoeial applications include assays for single and mixtures of drugs
analysis involving colour reactions (Colorimetric methods), test for tablet
dissolution, limit test for impurities, and assays of bulk drugs. Further
applications are for physiochemical measurements, such as pka or velocity
constants in enzymatic reactions. The scope of such applications has been
significantly extended by methods, which can confer additional specificity
namely difference spectrometry, derivative spectrometry; simultaneous 
equation method, absorbance ratio method, geometric correlation method and
orthogonal method (Anthony et al, 1986). 
1.5.1. Absorbance Ratio Method: 
It is a modification of the simultaneous equation procedure. It depends on the
property that, for a substance which obeys Beer's law at all wavelengths, the
ratio of absorbance at any two wavelengths is a constant value independent of
concentration or path length. For example, two different dilutions of the same 
substance (figure 1.5) give the same absorbance ratio A1/A2. The British 
pharmacopoeia also uses a ratio of absorbances at specified wavelengths in
certain confirmatory tests of identity. For example, cyanocobalamin exhibits
three λ max, at 278 nm, 361nm and 550nm. The A361/A550 is required to be 
3.30 + 0.15 and the A361/A278 to be 1.79 + 0.09.  
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Figure1.5: Absorption spectra of two different concentrations of a 
substance.(Reproduced from Beckett et al. 1997) 
In quantitative assay of two components in admixture by the absorbance ratio
method, absorbances are measured at two wavelengths (figure 1.6) one being 
the λ max of one of the component (λ2) and the other being  a wavelength of 
equal absorptivity of the two components (λ1). Two equations are constructed 
and treated simultaneously to get the absolute concentrations. This method
has been used for the assay of trimethoprim and sulphamethoxazole in co-
trimoxazole tablets (Beckett et al. 1997). 
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Figure1.6: Wavelengths for the assay of substances X and Y in admixture by 
the method of absorbance ratios. 
(Reproduced from Beckett et al. 1997) 
1.5.2. Standard Addition Method: 
Standard addition method may be used if no calibration curves have already 
been prepared and it is undesirable to prepare such a curve. This situation may 
arise if, for example, there is no time to prepare a calibration curve, or the 
interferences in the sample make it impossible to prepare a valid curve 
(Robinson, 1995).  
The method is widely practiced in atomic absorption and emission
spectrometry and has also found application in electrochemical analysis and
other areas. Equal volumes of the sample solution are taken, all but one, are
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separately ‘spiked’ with known and different amounts of the analyte and all 
are then diluted to the same volume. The instrument signals are then
determined for all those solutions and the results plotted as shown in figure 
1.7 
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Figure1- 7: Standard addition method curve 
(Reproduced from Robinson, 1995) 
1.5.3. Colorimetric Measurements: 
In colorimetric methods, a drug can be selectively transformed so that the 
spectrum of the product is shifted to the visible region. This will minimize 
interference caused by another drug, formulation components or biological 
substances, thereby conferring a further degree of specificity. Moreover, a 
drug with little or no useful absorption can be changed to more highly- 
absorbing chromophore; for example propofol (phenolic compound) was 
coupled with DCQ and gave a coloured reaction product (Gad-Kariem and 
Abounassif, 2000).
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There are several parameters, which require careful and critical consideration 
in colorimetry. Firstly, the colour reagent should be selective for the drug
molecule itself discriminating against degradation products, impurities, and
formulation excipients which might be present. Secondly, there should be a
control of parameters, which are likely to affect the colour reaction such as,
solvent, pH, temperature, reagent excess, order of mixing reagents, and other
related factors. 
Moreover, the time required to establish the chromophore should be carefully
monitored and assessed. Finally, the analytical performance should be
assessed in terms of recovery, precision, sensitivity and linear range (Anthony
et al. 1986). 
1.5.4. Effect of Solvents on Absorption Wavelengths: 
1. Red Shift: 
A molecule will dissolve in a solvent if solution leads to a lower energy 
system, that is, if energy changes favour solution. This can be expressed on an
energy diagram as in figure 1.8. 
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Figure1.8: The energy difference between π and π* levels is decreased in the 
polar solvents; the absorption wavelength increases (red shift) (Reproduced 
from Robinson, 1995) 
Electrons in a π* bonding orbital are more polar than electrons in a π bonding
orbital. Therefore, if a molecule is dissolved in a polar solvent the energy
difference will be less than the energy difference when the molecule is in a
non-polar solvent. 
As consequence, the absorption maximum is changed to a longer wavelength
in a polar solvent (Red shift) (Robinson, 1995). 
2. Blue Shift: 
The n electrons are known to be susceptible to hydrogen bonding more than 
electrons in a π orbital. The energy levels of n electrons decrease more than
the energy level of electrons in the π* orbital if hydrogens are available in the
solvent. 
An energy diagram of such a system is shown in figure1.9.The energy 
involved in the transition n →π* when the solvent is non-polar is less than the 
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energy involved in the same transition when the molecule is in a hydrogen
donating solvent. As a consequence, the absorption maximum in hydrogen
donating solvent will move to a shorter wavelength (blue shift) (Robinson,
1995). 
 
Figure1.9: Energy differences between n and π* levels increase in solvents 
that can provide H to the lone pair. The absorption wavelength decreases 
(blue shift) 
(Reproduced from Robinson, 1995) 
A molecule that contains both π orbital and n electrons may exhibit both a red
and a blue shift. 
Molecules that contain both π orbital and n electrons would be expected to
have an absorption spectrum in nonpolar non-hydrogen-donating solvent such
as hexane, shown in figure 1.10. 
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Figure1.10: Expected absorption spectrum of a molecule undergoing π→π* 
transitions and n→ π*. 
(Reproduced from Robinson, 1995) 
The absorption coefficient of the π→π* transition is considerably greater than
that of the n→ π* transition, thus generating a higher degree of absorption.
Also, in general, the n→ π* transitions occur at longer wavelengths because
the energy difference for this transition is lower. 
If we need to confirm these assignments, we would put the sample in a
solvent such as ethanol. Which is both polar and capable of donating
hydrogens; the polar nature would induce a red shift in the π → π* transition
and hydrogen donation would induce a blue shift in the n- π* transition. If our 
assignments were correct, then the expected absorption spectrum in ethanol 
would be as shown in figure 1.11. 
The combined evidence of the relative degree of absorption and the blue and
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red shifts occurring in ethanol strongly supports the idea that the molecule
contains both π bonds and n electrons (Robinson, 1995). 
 
Figure1.11: Absorption spectrum in ethanol of a molecule containing both π 
bonds and n electrons. 
(Reproduced from Robinson, 1995) 
1.5.5. Determination of Stoichiometry:  
 The spectrophotmetric method is particularly valuable for studying 
complexes of low stability. Consider the formation of a complex    Mn Lp. 
Where M is a metal ion and L is a ligand.  
Mn + Lp →   MnLp. 
The molar ratio of the two components of a complex is important.  
In a quantitative determination an excess of ligand should be added in order to 
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force equilibrium towards completion (Christian et al, 1978). 
1.5.5.1.Molar Ratio Method:  
In this method, the concentration of one component is kept fixed and that of
the other varied to give a series [L] [M] ratios. The absorbance of these 
solutions, measured at absorption maximum for the complex MnLp, increase 
linearly up to the molar ratio of the complex, at which virtually the whole
amount of both components is complexed (assuming little dissociation).
Further addition of component L cannot increase the absorbance, and the line
becomes horizontal or shows a break if component L absorbs at the same 
wavelength (figure 1.12). In rare cases an excess component L may cause a
decrease in absorbance owing to the stepwise formation of higher-order 
complexes that have smaller values at this wavelength (Christian et al, 1978). 
 
Figure1.12:  Molar ratio method 
(Reproduced from Christian, et al, 1978) 
a.  Component L. does not absorb at the wavelength of maximum
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absorption for the complex.  
b.  Component L absorbs slightly at the wavelength of maximum
absorption for the complex.  
c.  An excess of component L causes a decreases in absorbance of the
complex. 
 Molar ratio method was used for determination of the stoichiometry of the 
reaction between piperazine and ρ-benzoquinone (reaction ratio of ρ-
benzoquinone to piperazine was 1:4) (Gad-kariem et al, 1985).
1.5.5.2. Continuous- Variation Method (Job’s method):  
The molar ratios may also be varied by changing the concentrations of both
components while the total number of moles of both components is kept
constant this is termed the method of continuous variation or Job’s method
(Christian et al, 1978).  
Continuous -variation method (Job’s method) was used to investigate the
stoichiometry of the complexation reaction between fluvoxamine and 
chloranil (reaction ratio of fluvixamine to chloranil was 1:1) (Alhaider et all, 
1993). 
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Figure1.13: Continuous variation method 
(Reproduced from Christian et al, 1978) 
1.5.5.3. Slope Ratio Method: 
Similar to the fixed molar ratio method but taking only the linear part of the
plot when L is fixed and M is varied or M is fixed and L is varied.  The ratio
of the two slopes gives the reaction ratio (Christian et al, 1978). 
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2. Objectives 
1. Development and optimization of new spectrophotometric methods for 
the quantitative measurement of tobramycin and cefadroxil. 
2.     Validation of the developed methods. 
3. Application of the developed methods for quantitative measurement of 
tobramycin and cefadroxil in pharmaceutical dosage forms. 
4. Comparison between the developed methods and the official methods 
for quantitative analysis of tobramycin and cefadroxil. 
5. Study of the stoichiometry of the reaction between ascorbic acid and
tobramycin. 
6.      Statistical evaluations of the results. 
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3.1.Materials 
The materials used and their sources are summarized in the following table    
Table- (3-1): Materials                                                                            
Chemical Company Country 
TOBRA® Injection 
Tobramycin 80mg / 2ml 
Lot No : 003 
Manufacturing date: 10.2006 
Expiry date: 10.2009 
Shifa Aleppo-
Syria 
TOBRADEX® eye drops                    
Tobramycin 0.3%, Dexamethasone 
0.1%, Benzalkonium chloride 
Registration No.: EY-078-21798 
Lot No.: 08D14X 
Manufacturing date: 4.2008 
Expiry date: 3.2010 
Alcon-Couveur Belgium 
Tobramycin RS Medico Lab Syria 
MIDROXIL® capsules 
Cefadroxil 500mg/capsule 
Middle East 
Pharmaceutical 
Company 
Jordan 
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Batch No.: 080613B 
Registration No.: Cap/051/21110 
Manufacturing date: 6.2008 
Expiry date: 6.2011 
(MIDPHARMA) 
IBIDROXIL® Capsules 
Cefadroxil 500mg/capsule 
Batch No.: 070947A 
Registration No.: 21122/01 
Manufacturing date: 3.2007 
Expiry date: 3.2010 
 
GlaxoSmithKline S.A.E. 
LONGICEF® Capsules 
Cefadroxil 500mg/capsule 
Batch No.: 0620052 
Registration No.: CP/051/21157 
Manufacturing date: 8.2006 
Expiry date: 8.2009 
 
Kahira Pharm. Egypt 
Cefadroxil RS European 
Pharmacopeia 
Europe 
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3. 2.Reagents: 
The following table summarized the reagent used in the present study:- 
Table- (3-2):  
Chemical Company Country 
Dimethyl sulphoxide Loba Chemie India 
Dimethyl formamide (DMF) Merck KGA Germany 
Sodium hydroxide 
 
British Drug house  
(B.D.H.) 
England 
Ascorbic acid British Drug House 
(B.D.H.) 
England 
Acetonitrite HPLC grade British Drug house  
(B.D.H.) 
England 
Glacial acetic acid (analytical 
grade) 
British Drug house  
(B.D.H.) 
England 
3. 3.Instruments and Apparatus 
3.3.1.  JASCO V-530 UV/VIS spectrophotometer, Japan 
3.3.2.  Balance KERN ALS 120-4, Germany 
3.3.3. Water Bath, Gesellschaft fur Labortechnik mbH, Germany. 
3.3.4. Waters 600 liquid chromatograph with Waters 2996
detector and Enpower integrator. Wavelength 254 nm. A fixed loop injector 
(Rheodyne, 20 µl) was used to transfer the sample into the column (Variance, 
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C18, 4.6 mm x 25 cm, 5 µm).Mobile phase: a mixture of 4 volumes of 
acetonitrile R and 96 volumes of a 2.72 g/l solution of potassium dihydrogen 
phosphate R Flow rate 1.0 ml/minute. 
3.4. Methodology 
3.4.1.Tobramycin:- 
The following solutions were prepared:- 
Stock Solution of Standard tobramycin:- 
    0.2g of anhydrous tobramycin was accurately weighed and transferred into 
25 ml volumetric flask, dissolved in water, and then the volume was 
completed to 25ml with water (conc. 8000µg/ml)( solution A) 
Stock Solution of Tobramycin Injections:- 
    5ml of tobramycin injection (80mg/2ml) was transferred into 25 ml 
volumetric flask, dissolved in water, and completed to 25 ml with water 
(claimed conc. 8000µg/ml) (solution B). 
Stock Solution of Tobramycin Eye Drops (Tobradex):- 
5ml of the eye drops contains 3000µg/ml tobramycin, 0.1% dexamethasone. 
(solution C). 
Stock Solution of Tobramycin Eye Drops (Tobrex):- 
5ml of the eye drops contains 3000µg/ml tobramycin (solution D) 
Coupling reagent:- 
0.01 g of ascorbic acid was dissolved in 10 ml dimethyl sulfoxide to produce 
10 ml of 0.1 %w/v (solution E). 
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Coupling reagent:- 
0.01 g of ascorbic acid was dissolved in 10 ml dimethyl formamide to 
produce 10 ml of 0.1 %w/v (solution F). 
3.4.1.1.Methods and Experiments: 
3.4.1.1.1.Estimation of λ max   
60 µl of solution B was transferred into Stoppard glass tube. A volume 
of distilled water was added to adjust the volume to 100 µl, 1ml of solution E
(0.1%w/v) was added and the volume was completed to 10 ml using 
dimethylsulfoxide, in which the final solution contains 32 ug / ml tobramycin
RS. The solution was heated for 30 minutes.  
Blank was prepared similarly but without using solution B. 
UV/VIS spectrophotometer was run in scanning mode from 350 – 600
nm using above solution against its blank. 
3.4.1.1.2.Effect of Different Solvents on Absorption Spectra:- 
Serial dilutions were made from solution B. 20µl, 40µl, 60µl, 80µl and 100µl 
of this solution were transferred into stoppard glass tubes, then 80µl, 60µl, 
40µl, 20µl and 0.0µl of water were added to each tube  respectively. One ml
of freshly prepared solution E was added to each tube, the volumes were then 
completed to 10ml with dimethyl sulfoxide. Then heated for 30 minutes in
boiling water bath.  
Blank was prepared in the same manner  using 100 µl water instead of 100µl 
of standard tobramycin stock solution. 
UV/VIS spectrophotometer was run in scanning mode from 350 – 600 nm 
using above solutions against its blank. The established λmax was at 530 nm 
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and 390 nm for this reaction. 
The same procedure was carried for solution B using solution F instead of 
solution E and the volumes were completed to 10ml using dimethyl 
formamide instead of dimethylsulfoxide.  
Table-(3-3): Tobramycin Sample Solutions for Construction of 
calibration Curve using dimethylsulfoxide 
Solution
oN  
Solution 
B (µl) 
Distilled 
water(µl)  
Solution   
E (ml) 
Dimethyl 
sulfoxide(ml)
Tobramycin 
Sample   
Conc. 
(µg/ml) 
1  20  80 1.00  9.00 16.00 
2 40 60 1.00  9.00 32.00 
3 60 40 1.00  9.00 48.00  
4 80 20 1.00  9.00 64.00 
5  100 0.00  1.00   9.00 80.00 
Blank  0.00 100 1.00 9.00  0.00  
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Table-(3-4): Tobramycin Sample Solutions for Construction of 
calibration Curve using dimethyl formamide 
Solution
oN  
Solution 
B  (µl) 
Distilled 
water(µl)  
Solution F 
(ml) 
Dimethyl 
formamide 
(ml) 
Tobramycin 
Sample   
Conc. 
(µg/ml) 
1-1 20  80 1.00  9.00 16.00 
2-3 40 60 1.00  9.00 32.00 
3-3 60 40 1.00  9.00 48.00  
4-3 80 20 1.00  9.00 64.00 
5-3  100 0.00  1.00   9.00 80.00 
Blank  0.00 100 1.00  9.00  0.00  
 
3.4.1.2.Construction of calibration curve: 
 Serial dilutions were made from solution A. 20µl, 40µl, 60µl, 80µl and 100µl 
of this solution were transferred into Stoppered glass tubes, then 80µl, 60µl, 
40µl, 20µl and 0.0µl of water were added to each tube respectively. One ml of 
0.1 % w/v freshly prepared ascorbic acid was added to each tube, the volumes 
were then completed to 10ml with dimethyl sulfoxide. Then heated for 30
minutes in boiling water bath.  
Blank was prepared in the same manner  using 100 µl water instead of 100µl 
of standard tobramycin stock solution. 
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UV/VIS spectrophotometer was run in scanning mode from 350 – 600 nm 
using above solutions against its blank. The established λmax was at 532 nm
and 390 nm for this reaction. 
This procedure was repeated 3 times to obtain triplicate standard curve 
readings. 
Table- (3-5): Tobramycin RS Solutions for Construction of Calibration 
Curve 
Solution
oN  
Solution 
A (µl) 
Distilled 
water(µl) 
Solution E 
(ml) 
Dimethyl 
sulfoxide 
 (ml) 
Tobramycin 
RS conc. 
(µg/ml) 
1-1 20 80  1.00  9.00 16.00  
1-2 20 80 1.00  9.00 16.00  
1-3 20 80 1.00  9.00 16.00 
2-1 40 60 1.00  9.00 32.00 
2-2 40 60 1.00  9.00 32.00 
2-3 40 60 1.00  9.00 32.00 
3-1 60 40 1.00  9.00 48.00 
3-2 60 40 1.00  9.00 48.00 
3-3 60 40 1.00  9.00 48.00  
4-1 80 20 1.00  9.00 64.00 
4-2 80 20 1.00  9.00 64.00 
51 
 
4-3 80 20 1.00  9.00 64.00 
5-1 100 0.00 1.00  9.00 80.00 
5-2 100 0.00 1.00   9.00 80.00 
5-3 100 0.00  1.00   9.00 80.00 
Blank  0.00 100 1.00   9.00  0.00  
 
3.4.1.3.Construction of tobramycin sample Curve:- 
Serial dilutions were made from solution B. 20µl, 40µl, 60µl, 80µl and 100µl 
of this solution were transferred into Stoppered glass tubes, then 80µl, 60µl, 
40µl, 20µl and 0.0µl of water were added to each tube respectively. One ml of 
0.1 % w/v freshly prepared ascorbic acid was added to each tube then the 
volumes were completed to10ml with dimethyl sulfoxide. Then heated for 30
minutes in boiling water bath.  
Blank was prepared in the same manner but  using 100 µl water instead of 
100 µl of tobramycin sample stock solution.(Table 3-6) 
UV/VIS spectrophotometer was run in scanning mode from 350 – 600 nm
using above solutions against their blank to compare the UV absorption 
pattern with that of the standard. Readings afterwards were recorded at 532
nm and 390 nm. 
 This procedure was repeated 3 times to obtain triplicate sample curve 
readings. 
 
 
52 
 
Table (3- 6): Tobramycin Sample Solutions for Construction of 
calibration Curve 
Solution
oN  
Solution 
B (µl) 
Distilled 
water(µl)  
Solution E 
(ml) 
Dimethyl 
Sulfoxide 
(ml) 
Tobramycin 
Sample   
Conc. 
(µg/ml) 
1-1 20  80 1.00  9.00 16.00 
1-2 20 80 1.00  9.00 16.00 
1-3  20 80 1.00  9.00 16.00 
2-1 40 60 1.00  9.00 32.00 
2-2 40 60 1.00  9.00 32.00 
2-3 40 60 1.00  9.00 32.00 
3-1 60 40 1.00  9.00 48.00 
3-2 60 40 1.00  9.00 48.00 
3-3 60 40 1.00  9.00 48.00  
4-1  80 20 1.00  9.00 64.00 
4-2 80 20 1.00  9.00 64.00 
4-3 80 20 1.00  9.00 64.00 
5-1 100 0.00 1.00  9.00 80.00 
5-2 100 0.00 1.00   9.00 80.00 
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5-3 100 0.00  1.00   9.00 80.00 
Blank  0.00 100 1.00  9.00  0.00  
 
3.4.1.4.Assay of tobramycin:- 
Direct standard /sample comparison 
Injections sample:- 
To 60 µl of (solution B), 40 µl of water and 1 ml of 0.1 % w/v freshly 
prepared ascorbic acid were added, and the volume was completed to 10 ml 
with dimethylsulfoxide. 
Eye drops sample:- 
To 60 µl of each of  (solution C and D), 40 µl of water and 1 ml of 0.1 % w/v 
freshly prepared ascorbic acid were added, and the volume was completed to 
10 ml with dimethylsulfoxide 
Standard:- 
To 60 µl of (solution A), 40 µl of water and 1 ml of 0.1 % w/v freshly 
prepared ascorbic acid were added, and the volume was completed to 10 ml 
with dimethylsulfoxide. 
Blank:- 
To 100 µl of water 1 ml of 0.1 % w/v freshly prepared ascorbic acid were 
added, and the volume was completed to 10 ml with dimethylsulfoxide. 
The absorbances of both the sample and the standard were measured against
the blank and the content % was calculated. 
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3.4.1.5. Added recovery (%) Measurement:- 
The following solutions' were prepared:- 
Standard: 
40µl from (solution A) was transferred into stoppered glass tube, 60µl of 
water and 1.0 ml of 0.1% w/v freshly prepared ascorbic acid were added 
respectively before the volume was completed to 10 ml with 
dimethylsulfoxide. The absorbance was measured against the blank (Tube 1).
Injections 
The same procedure was used, using (solution B) in place of standard; the 
absorbance was then measured (Tube 2). 
Mixture: 
To 40 µl of (solution A), 40 µl of (solution B), 20µl of water and 1.0 ml of 
0.1 % w/v freshly prepared ascorbic acid solution were mixed before the
volume was completed to 10 ml with dimethylsulfoxide. The absorbance was 
then measured.  
The same procedure for the mixture was carried using each of solution C and
D instead of solution B. 
Blank was prepared as under ( 3.4.1.4) 
 3.4.1.6.Estimation of tobramycin-ascorbic acid complex reaction time:- 
Serial dilutions were made from (solution B). 20µl,40µl,60µl,80µl and 
100µl of this solution were transferred into stoppered glass tube, then 80µl, 
60µl, 40µl, 20µl and 0.0µl of water were added to each tube respectively. One
ml of 0.1 % w/v freshly prepared ascorbic acid was added to each tube. The 
solutions were heated in boiling water bath .The heating time with ascorbic 
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acid was varied (10, 20and 30 minutes) to study the effect of time on 
maximum color developments.  Blank was prepared similarly but without 
using solution A. After cooling, the absorbance was then measured. 
3.4.1.7.  Estimation of Colour Stability 
60 µl of freshly prepared solution B was transferred into Stoppered 
glass tube. A volume of distilled water was added to adjust the volume to
100µl , 1ml of solution E was added and the volume was completed to 10ml 
using dimethylsulfoxide, in which the final solution contains 48 ug / ml 
tobramycin. The solution was heated in boiling water bath for 30 minutes. 
Blank was prepared similarly but using water instead of solution B. 
After cooling, the absorbance was then measured at different time intervals
0,1,2 and 3 hours to check the stability of the formed color complex. 
3.4.1.8. Repeatability of the method 
20, 40 and 60 µl volumes of freshly prepared solution B were 
transferred into Stoppered glass tubes. A volume of distilled water was added 
to adjust the volume to 100 µl , 1ml of solution E (0.1%w/v) was added to 
each flask and the volume was completed to 10ml using dimethylsulfoxide, in 
which the final solution contains 16,32 and 48 ug/ ml tobramycin
respectively. The solutions were then heated in boiling water bath for 30
minutes. 
Blank was prepared similarly but without using solution B. 
The absorbance was measured against its blank. The method was repeated in
three consecutive days using fresh Solution B in order to evaluate the 
reproducibility of the method. 
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3.4.1.9. Interference Study (Matrix interference) :- 
          100 µl of solution C was transferred into three stoppered glass tube, 
1ml of solution E was added and the volume was then completed to 10ml with 
dimethylsulphoxide to obtain a solution containing (32µg/ml). The solutions 
were then heated for 30 minutes in boiling water bath. 
          At the same time, 40µl of solution B was transferred into three 
stoppered glass tubes, 60µl of water was added to each tube, 1ml of solution 
E was added and the volumes were then completed to 10ml with 
dimethylsulphoxide. The solutions were then heated in boiling water bath for
30 minutes. 
         Blank was prepared similarly but without using solution B or C. The 
Absorbance was then measured in the range of 350-600 nm. 
3.4.1.10. Standard addition method: 
70µl of solution C were transferred into four stoppered glass tubes; 
aliquot volumes (0, 10, 20 & 30 µl) of solution A were added to each tube. A 
volume of distilled water was added to each tube to adjust the volume to 
100µl, then 1 ml of solution E (0.1%w/v) was added to each tube. The volume 
was completed to 10ml using dimethylsulfoxide (Table3- 7). The solutions 
were heated on boiling water bath for 30 minutes.
Blank was prepared similarly but without using solution A and C.
The absorbance was measured at 532 and 390 nm against its blank. The 
absorbance was plotted against the final concentration of solution A in order 
to obtain Standard addition method graph.
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Table3- 7:  Aliquot Solutions for Standard Addition Method
* Theoretical conc.
3.4.1.11. Molar ratio method for determination of the Stoichiometry: 
Fixed ascorbic acid concentration and varied tobramycin concentration: 
0.048g of standard tobramycin was dissolved in 2ml water (concentration 
4.2x10-2M).10 µl, 20 µl, 30 µl, 40 µl, 50 µl, 80 µl and 100 µl of tobramycin
solution (4.2x10-2M) were transferred to stoppered glass tubes, then 90 µl, 80
µl, 70 µl, 60 µl, 50 µl, 20 µl, and 0.0 µl water were added respectively, then 
50µl of freshly prepared ascorbic acid solution (4.2x10-2M) were added to 
each flask. The volumes were then completed to 10ml with dimethyl 
sulfoxide. Solutions were heated for 30 minutes in a water bath at 100  C, 
and allowed to cool at room temperature. The absorbances of the resulting 
oN Solution
C
 (µl)
Solution
A
(µl)
Distilled
 Water
(µl)
Solution
E
 (µl)
Dimethyl-
sulfoxide
(µl)
Tobramycin 
  Conc.* 
(ug/ml)
1-1 70 0 30 1.00 9 0
1-2 70 0 30 1.00 9 0
2-1 70 10 20 1.00 9 8
2-2 70 10 20 1.00 9 8
3-1 70 20 10 1.00 9 16
3-2 70 20 10 1.00 9 16
4-1 70 30 0 1.00 9 24
4-2 70 30 0 1.00 9 24
Blank 0 0 100 1.00 9 0.00
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solutions were measured in the range 350-600 nm against the blank. The 
molar ratio of the reaction complex was obtained from a plot of tobramycin
molar ratio over that of ascorbic acid vs. absorbance values. 
 
Table-(3-8) :TobramycinAliquot Solutions for Molar Ratio Method 
 
 
Solution 
No. 
Sample 
solution 
(µl) 
Distilled 
water 
(µl) 
Ascorbic 
acid (µl) 
Dimethyl 
sulfoxide 
(ml) 
Tobramyc
in final 
conc. M 
Molar 
ratio 
tobra
mycin
/ 
ascorb
ic 
acid 
1 10 90 50 10 4.2 x10-4 0.2 
2 20 80 50 10 8.4 x10-4 0.4 
3 30 70 50 10 12.6 x10-4 0.6 
4 40 60 50 10 16.8 x10-4 0.8 
5 50 50 50 10 20.1 x10-4 1.0 
6 80 20 50 10 33.6 x10-4 1.6 
7 100 0.0 50 10 42 x10-4 2 
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3.4.2.Cefadroxil:-                                                                                               
The following solutions were prepared:- 
Stock Solution of Standard Cefadroxil:- 
    0.05g of anhydrous cefadroxil was accurately weighed, dissolved in about 
50 ml distilled water and transferred into 100 ml volumetric flask,  and then 
the volume was completed to 100 ml with water.10 ml from this solution was 
further diluted to 100 ml with water (conc.50 µg/ml), ( solution F). 
Stock Solution of Cefadroxil Capsules (Midroxil®, Ibidroxil® and 
Longicef®):- 
    A mass of the powdered sample equivalent to 0.05g of anhydrous
cefadroxil  was accurately weighed and transferred into 100 ml volumetric 
flask. About 80 ml of distilled water was added and the solution was shaken 
for 15 minutes to ensure disintegration and dissolution.  The volume was
completed to mark with distilled water and then filtered. 10 ml of the filtrate
was further diluted to 100 ml with distilled water (conc. 50µg/ml) (solution 
G,H and I respectively). 
Reagent:- 
4 g of NaOH was dissolved in 100 ml water to produce 100 ml of 1N NaOH
(solution J). 
3.4.2.1. Methods and Experiments: 
3.4.2.1.1. Estimation of Cefadroxil  λ max  in Water 
 5ml of solution F (50 µg / ml) was transferred into Stoppered glass 
tube. A volume of distilled water was added to adjust the volume to 10 ml 
using volumetric pipette (25µg/ml). 
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UV/VIS spectrophotometer was run in scanning mode from 200 – 500 nm 
using above solution against its blank ( distilled water) 
3.4.2.1.2. Estimation of Reaction product λ max  in Water 
5 ml of solution F (50 µg / ml) was transferred into Stoppered glass 
tube.  1ml of solution J was added. The solution was then heated in boiling 
water bath for 30 minutes. After cooling, the volume was completed to10ml
using distilled water, in which the final solution contains 25 µg / ml 
cefadroxil RS.   
Blank was prepared similarly but without using solution F. 
UV/VIS spectrophotometer was run in scanning mode from 200 – 500 nm 
using above solution against its blank. 
3.4.2.1.3. Estimation of cefadroxil-sodium hydroxide hydrolyzing product 
reaction time:- 
 5 ml of solution G was transferred into six Stoppered glass tubes.1 ml of 
solution J was added to each tube. One glass tube was left at room 
temperature and scanned at varied time (0,15,30,45 and 60 minutes). The 
other five solutions were  heated in boiling water bath .The heating time with 
NaOH was varied (0,15, 30,45 and 60 minutes) to study the effect of time on 
maximum product formation. Blank was prepared similarly but using water 
instead of solution F. After cooling, the volumes were completed to 10 ml 
using distilled water. The absorbance was then measured. 
3.4.2.1.4. Estimation of Product Stability 
3ml of solution G was transferred into Stoppered glass tube, 2ml of 
water and 1ml of solution J were added. The solution was heated for 30
minutes in a boiling water bath. After cooling the volume was completed to
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10ml with water. Blank was prepared similarly but using water instead of 
solution F. 
 The absorbance was then measured at different time intervals 0,1,2 and 3
hours to check the stability of the formed product.                      
3.4.2.2. Construction of calibration curve: 
   Aliquot volumes (1-5ml) of solution F (50 ug / ml) were each  transferred 
into Stoppered glass tubes, and then 4ml, 3ml, 2ml, 1ml and 0ml of water 
were added to each tube respectively. 1 ml of 1N NaOH was added to each 
tube before heating for 30 minutes in a boiling water bath. After cooling, the
volumes were then completed to 10 ml with water. Blank was prepared in the 
same manner but  using 5 ml water instead of 5 ml of standard cefadroxil
stock solution.                      
The same procedure was repeated for solution   G and I   (Tables 3-9& 
3-10). UV/VIS spectrophotometer was run in scanning mode from 300 – 500
nm using the above solutions against blank. The λmax for this reaction was 
found to be 342 nm. This procedure was repeated 3 times for both sample and 
standard to obtain triplicate standard curve readings 
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Table-(3-9) : Cefadroxil RS Solutions for Construction of Calibration
Curve 
Solution 
No 
Solution F 
(ml) 
Distilled 
water (ml)
Solution J 
(ml) 
Distilled 
water (ml)
Cefadroxil 
RS Conc. 
(ug/ml) 
1-1 1 4 1 4 5 
1-2 1 4 1 4 5 
1-3 1 4 1 4 5 
2-1 2 3 1 4 10 
2-2 2 3 1 4 10 
2-3 2 3 1 4 10 
3-1 3 2 1 4 15 
3-2 3 2 1 4 15 
3-3 3 2 1 4 15 
4-1 4 1 1 4 20 
4-2 4 1 1 4 20 
4-3 4 1 1 4 20 
5-1 5 0 1 4 25 
5-2 5 0 1 4 25 
5-3 5 0 1 4 25 
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Table-(3-10) : Midroxil ® Sample Solutions for Construction of 
Calibration Curve 
Solution 
No 
Solution 
G (ml) 
Distilled 
water 
(ml) 
Solution J 
(ml) 
Distilled 
water 
(ml) 
Cefadroxi
l sample 
Conc. 
(ug/ml) 
1-1  1 4 1 4 5 
1-2 1 4 1 4 5 
1-3 1 4 1 4 5 
2-1 2 3 1 4 10 
2-2 2 3 1 4 10 
2-3 2 3 1 4 10 
3-1 3 2 1 4 15 
3-2 3 2 1 4 15 
3-3 3 2 1 4 15 
4-1 4 1 1 4 20 
4-2 4 1 1 4 20 
4-3 4 1 1 4 20 
5-1 5 0 1 4 25 
5-2 5 0 1 4 25 
5-3 5 0 1 4 25 
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Table-(3-11) : Longicef® Sample Solutions for Construction of 
Calibration Curve 
Solution 
No 
Solution 
G (ml) 
Distilled 
water 
(ml) 
Solution J  
(ml) 
Distilled 
water 
(ml) 
Cefadroxi
l sample 
Conc. 
(ug/ml) 
1-1  1 4 1 4 5 
1-2 1 4 1 4 5 
1-3 1 4 1 4 5 
2-1 2 3 1 4 10 
2-2 2 3 1 4 10 
2-3 2 3 1 4 10 
3-1 3 2 1 4 15 
3-2 3 2 1 4 15 
3-3 3 2 1 4 15 
4-1 4 1 1 4 20 
4-2 4 1 1 4 20 
4-3 4 1 1 4 20 
5-1 5 0 1 4 25 
5-2 5 0 1 4 25 
5-3 5 0 1 4 25 
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3.4.2.3.Assay of cefadroxil Capsules:- 
Direct standard /sample comparison  
Assay Using Cefadroxil RS, Longicef® , Midroxil®  and Ibidroxil®  
Solutions  
Three different solutions of Cefadroxil RS, Longicef®,Midroxil®  and 
Ibidroxil® were prepared at the same time. The absorbance of each solution
was measured at 342 nm against its blank. 
3.4.2.3.1. Preparation of Cefadroxil RS Solution 
3 ml of solution F (15 ug / ml) were transferred into three Stoppered 
glass tubes. A volume of distilled water was added to each tube to adjust the 
volume to 5 ml using volumetric pipette, then 1ml of solution J was added to 
each tube.The solutions were heated in a boiling water bath for 30 minutes. 
After cooling, the volumes were completed to 10 ml using distilled water. 
Blank was prepared similarly but without using solution F. 
 3.4.2.3.2. Preparation of Midroxil® Solution 
3 ml of solution G (15 ug / ml) were transferred into three Stoppered 
glass tubes. A volume of distilled water was added to each tube to adjust the 
volume to 5 ml using volumetric pipette, then 1ml of solution J was added to 
each tube.The solutions were heated in a boiling water bath for 30 minutes. 
After cooling, the volumes were completed to 10 ml using distilled water. 
3.4.2.3.3. Preparation of Ibidroxil® Solution 
3 ml of solution H (15 ug / ml) were transferred into three Stoppered 
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glass tubes. A volume of distilled water was added to each tube to adjust the 
volume to 5 ml using volumetric pipette, then 1ml of solution J was added to 
each tube.The solutions were heated in a boiling water bath for 30 minutes. 
After cooling, the volumes were completed to 10 ml using distilled water. 
3.4.2.3.4.Preparation of Longicef® Solution 
3 ml of solution I (15 ug / ml) were transferred into three Stoppered
glass tubes. A volume of distilled water was added to each tube to adjust the 
volume to 5 ml using volumetric pipette, then 1ml of solution J was added to 
each tube.The solutions were heated in a boiling water bath for 30 minutes. 
After cooling, the volumes were completed to 10 ml using distilled water. 
3.4.2.4. Added recovery (%) Measurement:- 
The following solutions' were prepared:- 
Standard: 
2ml from (solution F) was transferred into Stoppered glass tube, 3ml of water 
and 1.0 ml of solution J were added respectively, heated for 30 minutes. After 
cooling the volume was completed to 10 ml with water. The absorbance was 
measured at 342nm against the blank. 
Capsules 
The same procedure was used, using (solution G) in place of standard; the 
absorbance was measured at 342 nm. 
Mixture: 
To 2 ml of (solution F), 2 ml of (solution G), 1.0ml of water and 1.0 ml of 
solution J were mixed, heated for 30 minutes. After cooling the volume was 
completed to 10 ml with water. The absorbance was measured at 342 nm. 
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Blank was prepared as under  
3.4.2.5.Repeatability of the method 
2, 3 and 4ml volumes of freshly prepared solution F were transferred 
into Stoppered glass tubes. A volume of distilled water was added to adjust
the volume to 5ml , 1ml of solution J (1N) was added to each flask.The 
solutions were then heated in boiling water bath for 30 minutes. After cooling 
the volume was completed to 10ml with water, in which the final solution 
contains 20,30 and 40 ug/ ml cefadroxil respectively. Blank was prepared 
similarly but without using solution F. 
The absorbance was measured against its blank. The method was repeated in
three consecutive days using fresh Solution F in order to evaluate the 
reproducibility of the method. 
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4.Results 
4.1.Tobramycin: 
4.1.1. Absorption Spectrum of Tobramycin-Ascorbic acid complex             
The sample of tobramycin (48 ug / ml) prepared to estimate λmax of the 
complex formed with ascorbic acid (section3.4.1.1.1) gave a coloured 
solution. The solution   showed two peaks at wavelength 532 nm and 390nm 
with a detectable absorption reading at 0.346 and 1.013 respectively. Figure 
(4-1) 
 
Figure 4-1: UV/VIS  absorption spectra of tobramycin-ascorbic acid 
complex 
4.1.2. Effect of Different Solvents 
The effect of different solvents, namely, dimethylformamide and 
dimethylsulfoxide, was studied. The UV/VIS spectrum of the tobramycin-
ascorbic acid reaction product in each solvent was obtained as shown in figure 
(4-2) & (4-3) for dimethylformamide and dimethylsulfoxide respectively. 
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Figure 4-2: UV/VIS  absorption spectra of tobramycin-ascorbic acid 
complex using dimethylformamide as solvent 
 
 
Figure 4-3: UV/VIS  absorption spectra of tobramycin-ascorbic acid 
complex using dimethylsulfoxide as solvent 
Calibration curves were constructed by using the UV/VIS results of the 
reaction product in different solvents (section3.4.1.1.2). The results are shown 
in table-(4-1) and figure (4-4) for dimethylformamide and table (4-2) and 
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figure (4-5) for dimethylsulfoxide.
Table-(4-1) :  Calibration Curve Using Dimethyl formamide as Solvent 
Conducted during 3 Different Days (λ Max 532 nm)  
Conc. 
(µg\ml) 
A A A Mean A SD 
16  0.070 0.070 0.080  0.073 5.8 x10-3 
32  0.104 0.106 0.110 0.1067 3.05 x10-3 
48  0.163 0.158 0.161 0.1607 2.5 x10-3 
64 0.185 0.186 0.205  0.1920 1.1 x10-2 
80  0.272  0.273 0.280  0.2750  4.3 x10-3  
r = 0.991     Slope = 0.003     Intercept = 0.007
Figure-(4-4) : Calibration curve of the reaction product using dimethyl 
formamide as solvent (conc µg/ml)(Mean Absorbance) 
 
71 
 
Table-(4-2) :  Calibration Curve Using Dimethyl sulphoxide as Solvent 
Conducted during 3 Different Days (λ Max 532 nm) 
 
Conc. 
(µg\ml) 
A A A Mean A SD 
16  0.121 0.120 0.120 0.1203 5.77 x10-4 
32  0.235 0.224 0.224 0.2277 6.35 x10-3
48 0.346 0.347 0.348 0.347 1.0 x10-3
64 0.457 0.438 0.438 0.4443 1.0 x10-2
80  0.562  0.526 0.536  0.5413  1.8 x10-2
r = 0.9991     Slope = 0.0068     Intercept = 0.0088
Figure-(4-5) : Calibration curve of the reaction product using dimethyl 
sulphoxide as solvent (conc µg/ml)(Mean absorbance) 
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4.1.3. Construction of Calibration Curve 
         The Absorbance at  λmax  532nm and 390nm was plotted against the final 
concentration in order to obtain a calibration graph. 
The procedure was carried out three times tables (4-3), (4-4) &(4-5) and 3 
calibration curves were plotted figures (4-6) to  (4-11). 
Table-(4-3):  Absorption of Tobramycin RS Solutions 1 
Sample # Conc. ug/ml 
Conc. 
%(w/v) 
 
Conc.M 
Abs at 
λmax 
532nm 
Abs at 
λmax 
390nm 
1 16 0.0016 2.8 x10-5 0.112 0.367 
2 32 0.0032 5.6 x10-5 0.225 0.691 
3 48 0.0048 8.4 x10-5 0.352 1.064 
4 64 0.0064 11.8 x10-5 0.441 1.312 
5 80 0.008 14 x10-5 0.536 1.571 
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  Figure-(4-6): Tobramycin RS Calibration Curve using (µg/ml) 
Concentrations (curve1, λmax 532nm) 
 
 
    Figure-(4-7): Tobramycin RS Calibration Curve using (µg/ml) 
Concentrations (curve1, λmax 390nm) 
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Table-(4-4):  Absorption of Tobramycin RS Solutions 2 
Sample # Conc. ug/ml 
Conc. 
%(w/v) 
Conc. M Abs at 
λmax 
532nm 
Abs at 
λmax 
390nm 
1 16 0.0016 2.8 x10-5 0.111 0.341 
2 32 0.0032 5.6 x10-5 0.225 0.661 
3 48 0.0048 8.4 x10-5 0.347 1.034 
4 64 0.0064 11.8 x10-5 0.435 1.302 
5 80 0.008 14 x10-5 0.532 1.565 
                   
 
Figure-(4-8): Tobramycin RS Calibration Curve using (µg/ml) 
Concentrations (curve2, λmax 532nm) 
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Figure-(4-9): Tobramycin RS Calibration Curve using (µg/ml) 
Concentrations (curve2, λmax 390nm) 
 
Table-(4-5):  Absorption of Tobramycin RS Solutions 3 
Sample # Conc. ug/ml 
Conc. 
%(w/v) 
Conc. M Abs at 
λmax 
532nm 
Abs at 
λmax 
390nm 
1 16 0.0016 2.8 x10-5 0.110 0.323 
2 32 0.0032 5.6 x10-5 0.229 0.729 
3 48 0.0048 8.4 x10-5 0.347 1.043 
4 64 0.0064 11.8 x10-5 0.445 1.383 
5 80 0.008 14 x10-5 0.534 1.623 
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Figure-(4-10): Tobramycin RS Calibration Curve using (ug/ml) 
Concentrations (curve3, λmax 532nm) 
 
 
 
Figure-(4-11): Tobramycin RS Calibration Curve using (ug/ml) 
Concentrations (curve3, λmax 390nm) 
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4.1.4. Statistics of calibration curves                                                                 
In order to validate the results, statistic analysis was done for each curve and 
the mean value of each curve readings was calculated ,table ( 4-6). The mean 
value of absorbancses was plotted against final concentrations to construct a 
final calibration curve ,figure(4-12). 
 Table-(4-6): Statistical Analysis of Calibration curves 
Absorbance 
Sample 
# 
Conc. 
µg/ml Conc. 
%w/v 
Molar conc. 
mol/L 
Abs Mean SD 
1 0.112 
2 0.111 
3 
16 0.0016 
 
 
2.8 x10-5 
 0.110 0.1110 
1 x10-3 
1 0.225 
2 0.225 
3 
32 
0.0032 
 
5.6 x10-5 
 0.229 0.2263 
2.3 x10-3 
1 0.352 
2 0.347 
3 
48 
0.0048 
 
8.4 x10-5 
 0.347 0.3487 
2.9 x10-3 
1 0.441 
2 0.435 
3 
64 
0.0064 
 11.8 x10-5 0.445 0.4403 
5 x10-3 
1 0.536 
2 0.532 
3 
80 
0.008 
 14 x10-5 0.534 0.5340 
2 x10-3 
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Figure-(4-12): Tobramycin Calibration Curve Using Concentrations 
(µg/ml)   (Mean of Absorbance) 
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4.1.4.1. Error of the slope and the intercept and determination of 
detection and quantification limits:-
Error for the slope (b), intercept (a), and the limit of detection and the limit of 
quantification were all determined statistically (Miller and Miller). The results 
are illustrated in table.  Table (4-7). 
Xi  Xi²  Yi  Ŷi  ( Yi ‐  Ŷi)²  ( Xi – X`)² 
0 0 0 0.0067 4.49 X10-05  
16 256 0.1110 0.1147 1.369 X10-05 1024 
32 1024 0.2263 0.2227 1.296 X10-05 256 
48 2304 0.3487 0.3307 32.4 X10-05 0 
64 4096 0.4403 0.4387 0.256 X10-05 256 
80 6400 0.5340 0.5467 0,161 X10-05 1024  
 
Sy/x = √ ∑i (Yi - Ŷi) ² / n-2 = √ 39.97×10-5 /3 = 0.01153                              
Sb = Sy/x / √ ∑i (Xi – X`) ² = 0.01153/√ 50.6 = 1.6×10-3 
For t value for (n-2) = 3 the 99% confidence level is 5.84, the 99% confidence limit 
for the b is thus 
b=0.0068±5.84×1.6x10-3 
Slope (b) = 0.0068± 0.0094 
Sa = Sy/x√ ∑i Xi² / n∑i (Xi – X`) ² 
= 0.01153 √ 14080/5 /2560 = 0.0121 
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So the confidence limit is  
a = 0.0067± 5.84× 0.0121 
Intercept (a) = 0.0067 ± 0.071 
Where: 
Sy/x = Standard deviation of y along x 
Sb = Standard deviation for the slope  
Sa = Standard deviation for the intercept 
Limit of detection 
Y = YB + 3SB 
Y = 0.0067 + 3×0.01153 
Y = 0.04129 
Y= bx + a 
0.04129= 0.0068 x +0.0067 
So the limit of detection is 5.08µg/ml 
 
Limit of Quantification: 
Y = YB + 10 SB 
Y = 0.0067 + 10×0.01153 = 0.122 
Y = bx + a 
0.122 = 0.0068 x +0.0067 
X = 16.95 µg/ml 
So the limit of quantification is 16.95µg/ml  
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4.1.5. Construction of Sample Curve 
The absorbance of solutions was measured at the range of 600-350 nm 
against their blank. The Absorbance was plotted against the final
concentration in order to obtain a calibration graph. 
The procedure was carried out three times tables (4-8), (4-9) & (4-10)
and 3 calibration curves were plotted figures (4-13) to (4-18).  
Table-(4-8):  Absorption of Tobramycin Sample Solutions 1 
Sample # Conc. ug/ml 
Conc. 
%(w/v) 
Conc. M Abs at 
λmax 
532nm 
Abs at 
λmax 
390nm 
1 16 0.0016 2.8 x10-5 0.121 0.367 
2 32 0.0032 5.6 x10-5 0.235 0.732 
3 48 0.0048 8.4 x10-5 0.346 1.034 
4 64 0.0064 11.8 x10-5 0.457 1.383 
5 80 0.008 14 x10-5 0.562 1.617 
 
 
 
 
82 
 
Figure-(4-13): Tobramycin Sample Calibration Curve using (µg/ml) 
Concentrations (curve1, λmax 532nm)  
 
Figure-(4-14): Tobramycin Sample Calibration Curve using (µg/ml) 
Concentrations (curve1, λmax 390nm) 
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Table –(4-9): Absorption of Tobramycin Sample  Solutions 2 
Sample # Conc. ug/ml 
Conc. 
%(w/v) 
Conc. M Abs at 
λmax 
532nm 
Abs at 
λmax 
390nm 
1 16 0.0016 2.8 x10-5 0.120 0.346 
2 32 0.0032 5.6 x10-5 0.224 0.652 
3 48 0.0048 8.4 x10-5 0.347 1.024 
4 64 0.0064 11.8 x10-5 0.438 1.251 
5 80 0.008 14 x10-5 0.532 1.565 
 
 
Figure-(4-15): Tobramycin Sample Calibration Curve using (µg/ml) 
Concentrations (curve2, λmax 532nm) 
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Figure-(4-16): Tobramycin Sample Calibration Curve using (µg/ml) 
Concentrations (curve2, λmax 390nm) 
 
Table-(4-10):  Absorption of Tobramycin Sample  Solutions 3 
Sample # Conc. ug/ml 
Conc. 
%(w/v) 
Conc. M Abs at 
λmax 
532nm 
Abs at 
λmax 
390nm 
1 16 0.0016 2.8 x10-5 0.120 0.346 
2 32 0.0032 5.6 x10-5 0.224 0.652 
3 48 0.0048 8.4 x10-5 0.348 1.033 
4 64 0.0064 11.8 x10-5 0.438 1.251 
5 80 0.008 14 x10-5 0.536 1.571 
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Figure-(4-17): Tobramycin Sample Calibration Curve using (µg/ml) 
Concentrations (curve3, λmax 532nm) 
 
  
  
Figure-(4-18): Tobramycin Sample Calibration Curve using (µg/ml) 
Concentrations (curve3, λmax 390nm) 
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4.1.6. Assay of Tobramycin injections by the Proposed Method:  
Direct standard/sample comparison was used to assay tobramycin 
injection by the proposed method (section 3.4.2.6 ). The following 
formula was adopted to calculate content of tobramycin, as % w/w of the 
injection considering equal sample and standard concentrations  
A Sample / A STD × 100 
A Sample: Absorbance of the sample  
A STD: Absorbance of the standard 
The results are shown in table (4-11) 
 
 
4.1.6.1. Assay of injections by the Proposed Method using conc. 
48ug/ml:- 
Table-(4-11): Absorbance statistics 
 
 
 
  
Absorbance
1 
Absorbance  
2 
Absorbance 
3 
Mean 
Absorbance 
SD 
Standard 0.352 0.347 0.347 0.3487 0.0028
Tobra(sample) 0.348 0.347 0.346 0.347 0.001 
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Table- (4-12): Content % statistics  
Sample 
ID 
ABS 
 
Content 
(% w/v) 
Mean 
(%w/v)
SD 
(w/v) 
Value range 
 
1 0.348 98.86 
2 0.347 100 
3 0.346 99.7 99.5 0.59 99.5±0.59% 
 
     Also the following formula was adopted to calculate content of 
tobramycin, as % w/w of the injection directly from the sample and 
standard curves:-  
(Slope of sample curve/Slope of standard curve) x100 
          -Mean slope of the standard curve=0.0068 
-Mean slope of the sample curve=0.0068 
Content %=( 0.0068/.0068)x100=100% 
4.1.6.2. Assay of injections using the official method (Disc Diffusion 
Technique):- 
Table (4-13):- 
Micro-organism 
Tested 
Standard 
Inhibition Zone 
Test Inhibition    
Zone 
% 
Staphylococcus 
aureus 
24mm 24mm 100 
Pseudomonas spp. 25mm 25mm 100 
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E-coli 12mm 12mm 100 
Klebsiella spp. 25mm 25mm 100 
 
4.1.6.3. Assay of Eye drops by the Proposed Method using conc. 
32ug/ml:- 
Table-(4-14): Absorbance statistics 
Table (4-15): Content % Statistics  
Sample 
ID 
ABS 
 
Content 
(% w/v) 
Mean 
(%w/v)
SD 
(w/v) 
Value range 
 
0.179 50.9 
0.176 50.7 
Tobradex 0.173 49.9 50.5 0.53 50.5±0.53% 
0.323 91.8 
0.321 92.5 
Tobrex 0.319 91.9 92.1 0.38 92.1± 0.38% 
  
Absorbance
1 
Absorbance  
2 
Absorbance 
3 
Mean 
Absorbance 
SD 
Standard 0.352 0.347 0.347 0.3487 0.0028
Tobradex® 
(sample) 0.179 0.176 0.173 0.176 
0.003 
Tobrex® 
(sample) 0.323 0.321 0.319 0.321 
0.002 
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4.1.7. Added recovery (%) by the Proposed Method: 
To determine the added recovery (%) by the proposed method 32 µg/ml 
of standard tobramycin solution, 32 µg/ml of tobramycin injection 
solution and a mixture of both were used (section 3.4.1.5.). The 
recoveries were calculated according to the following formulae: 
A mix-A sample= A standard (1) 
Recovery (%) = (A standard (1) / A standard) x 100 
Table- (4-16): Added recovery (%) of the Proposed Method  
 
Recovery % = 100.9±2.25 
4.1.8. Estimation of tobramycin-ascorbic acid product reaction time:-  
To optimize the reaction time of the colour produced from the reaction of 
tobramycin with ascorbic acid, a sample of tobramycin was prepared and 
the absorbance was recorded at different time intervals. The obtained 
results are shown in table (4-15) and figures (4-19), (4-20) &(4-21). 
  
  
  
SDMeanRecovery (%) A standard A standard (1) A sample A mix 
99.60.2250.2240.2240.4481
103.50.2290.2370.2350.4722
2.252 100.9
99.60.2290.2280.2310.4593
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Table- (4-17): Estimation of tobramycin-ascorbic acid complex 
reaction time . 
 
  
  
  
  
  
 
 
 
 
  
Figure-(4-19): (Tobramycin –ascorbic acid) product Curve after 10 
minutes  
  
Absorbance/time(minutes) Conc. 
ug/ml 10  20  30  
16 0.029 0.062 0.120 
32 0.052 0.126 0.224 
48 0.065 0.180 0.347 
64 0.088 0.253 0.438 
80 0.121 0.321 0.532 
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Figure-(4-20): (Tobramycin –ascorbic acid) product Curve after 20 
minutes  
  
  
Figure-(4-21): (Tobramycin –ascorbic acid) product Curve after 30 
                                                                  minutes  
  
 
92 
 
4.1.9. Stability of the Color using 48 µg\ml of tobramycin sample  
To study the stability of the color produced from the reaction of 
tobramycin with ascorbic acid a sample of tobramycin was prepared and 
the absorbance was recorded at different time intervals. The obtained 
results are shown in table (4-18) , figure (4-22).  
Table (4- 18): Absorbance of (tobramycin–ascorbic acid) reaction 
product(Done For 48 µg\ml of tobramycin sample)  during 3 hours:-  
Absorbance Time (Hour)  
0.347 0 
0.350 1 
0.353 2 
0.353 3 
 
  
Figure-(4-22) :-Absorbance of (tobramycin –ascorbic acid) reaction                  
product versus time (hours). 
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4.1.10. Reproducibility& repeatability:-  
In order to evaluate between - days variation (reproducibility) and 
within day variation (repeatability) 3 different conc. of tobramycin 
solutions were assessed in three different days table(4-19) and within the 
same day table(4-20). 
Table (4-19):  Tobramycin sample absorption in Different days 
Absorbance Conc. 
ug/ml Day1 Day 2 Day 3 Mean SD 
16 0.121 0.120 0.120 0.1203 5.77 x 10-04 
32 0.225 0.224 0.224 0.2243 5.77 x 10-04 
48 0.347 0.346 0.348 0.3470 1.00 x 10-03 
.  
Table -(4-20):- Tobramycin Sample Absorption on the same day 
Absorbance Conc. 
ug/ml 1 2 3 Mean SD 
16 0.111 0.110 0.110 0.1103 0.5x 10-03 
32 0.225 0.229 0.225 0.2263 2.3 x 10-03 
48 0.347 0.347 0.346 0.3467 0.58 x 10-03 
 
4.1.11. Interfernce Study:- 
   The results obtained are shown in the following table (4-21) 
Table-(4-21): Tobra® and Tobradex® Samples Absorption:- 
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Sample Sample 1 Sample 2 Sample 3 Mean SD 
Tobra® 0.224 0.224 0.225 0.2243 0.58x 10-
03 
Tobradex® 0.115 0.117 0.119 0.117 2x 10-03 
 
Interference % = (0.117/0.2243) x 100 = 52% 
4.1.12. Standard addition method 
Standard addition method samples were prepared by adding aliquot 
volumes (0,10,20,30 µl) of tobramycin RS  to a fixed Tobradex sample 
solutions (21 ug / ml). A graph was drawn (Figure4-23) to evaluate the 
possible interference that may occur.   
Table4-22: Standard Addition Method Results 
Sample 
#
Tobramycin
conc. *
ug/ml
Standard
conc. 
ug/ml  Abs1 Abs2  Mean
1 21 0 0.095 0.094 0.0945
2 21 8 0.142 0.139 0.1410
3 21 16 0.192 0.196 0.1940
4 21 24 0.235 0.249 0.2420
 
The following equation was adopted to calculate recovery % from 
the standard addition method graph (Figure4-23): 
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Recovery % = (X axis contribution / tobramycin stated amount) X 
100% 
 
 
Figure 4-23: Standard addition method 
Concentration of the sample= 0.0936/0.0062= 15.1 µg/ml 
Recovery % was found to be 71.9 % 
4.1.13. Study of the Stoichiometry of the reaction using molar ratio 
method:  
Fixed Ascorbic acid Concentration against different Tobramycin 
Concentrations. 
4.2x10-2 molar solutions of both tobramycin RS and ascorbic acid were 
prepared as in section (3.4.2.11). To 10 µl, 20 µl, 30 µl, 40 µl, 50 µl, 80 
µl and 100 µl of tobramycin solution (4.2x10-2M), 50µl freshly prepared 
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ascorbic acid was added before their volumes were completed to 10ml 
with dimethylsulfoxide , then scanned using spectrophotometer. 
The results obtained for the study of the stoichomitry of the reaction are 
shown in table (4-23) and figure (4-24).  
Table-(4-23): Molar Ratio Method (fixed ascorbic acid conc.) 
 
Conc. of 
tobramycin 
(M) 
No of µl of 
tobramycin 
Absorbance 
4.2 x10-4 10 
0.066 
8.4 x10-4 20 
0.116 
12.6 x10-4 30 
0.147 
16.8 x10-4 40 
0.160 
20.1 x10-4 50 
0.164 
33.6 x10-4 80 
0.164 
42 x10-4 100 
0.168 
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(Y) axis = absorbance 
(x) axis =numbers of µl of tobramycin 
Figure-(4-24) : Molar ratio curve ascorbic acid (fixed concentration), 
tobramycin (varied concentration) 
 
 
 
 
 
 
 
 
 
 
 
 
  
98 
 
:fadroxilCe ..24 
Absorption Spectrum of Cefadroxil in water. .1.24 
The sample of cefadroxil (25 ug / ml) showed peak at wavelength 264 nm 
with a detectable absorption reading at 0.623µg/ml  (Figure 4-25) 
                              
 
Figure 4-25: UV/VIS  absorption spectrum of cefadroxil in water 
4.2.2.Absorption Spectrum of Cefadroxil-NaoH product                                           
The sample of  cefadroxil (25 ug / ml) prepared to estimate λmax of the 
product formed with sodium hydroxide (section 3.4.2.1.2.) gave a 
coloured solution. The solution   showed peak at wavelength 342 nm with 
a detectable absorption reading 0.551 (Figure4-26) 
 
Figure 4-26: Absorption spectrum of cefadroxil-NaOH product 
99 
 
4.2.3. Estimation of cefadroxil-sodium hydroxide hydrolyzation 
product reaction time:-  
To optimize the reaction time of the product from the reaction of 
cefadroxil with NaOH, a sample of cefadroxil was prepared and the 
absorbance was recorded at different time intervals. The obtained results 
are shown in table 4-24, figure 4-27. 
Table-(4-24): Estimation of cefadroxil-sodium hydroxide hydrolysed 
product reaction time:-  
    60 
minutes
    45 
minutes
    30 
minutes 
    15 
minutes 
0 timeWave 
length 
0.1730.1780.2110.2510.172342
0.0810.0630.0490.0380.0482
At 
room 
temp. 
0.653 0.6510.580 0.4650.172342
ng* ng*ng*ng*ng*482
With 
heating 
            
Figure (4-27): Absorbance of (cefadroxil- sodium hydroxide product) 
vs heating time  
ng*: negligible absorbance.  
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4.2.4. Estimation of product stability  
 To study the stability of the product from the reaction of cefadroxil with 
sodium hydoxide a sample of cefadroxil was prepared and the absorbance 
was recorded at different time intervals. The obtained results are shown in 
table 4-25, figure 4-28 
Table (4- 25): Absorbance of the reaction product (Done For 15 
µg\ml of cefadroxil sample)  during 3 hours:-  
Absorbance Time (Hour)  
0.340 0 
0.348 1 
0.352 2 
0.355 3 
 
  
Figure (4-28):-Absorbance of (cefadroxil-sodium hydroxide) reaction 
product versus time (hours). 
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4.2.5. Construction of Calibration Curve 
             The Absorbance at  λmax 342nm was plotted against the final 
concentration in order to obtain a calibration graph. 
The procedure was carried out three times Tables 4-26, 4-27, 4-28) and 3 
calibration curves were plotted figures 4-29, 4-30, 4-31  
Table (4-26):  Absorption of Cefadroxil RS Solutions 1 
Sample # Conc. ug/ml 
Conc. 
%(w/v) 
 
Conc.M 
Abs at 
λmax 
342nm 
1 5 0.0005 1.38X 10-05 0.125 
2 10 0.001 2.75X 10-05 0.230 
3 15 0.0015 4.14X 10-05 0.346 
4 20 0.002 5.52 X 10-05 0.444 
5 25 0.0025 6.9 X 10-05 0.551 
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Figure (4-29)-: Cefadroxil RS Curve using (ug/ml) Concentrations 
         (curve 1)  
 
Table (4-27): Absorption of Cefadroxil RS Solutions 2 
Sample # Conc. ug/ml 
Conc. 
%(w/v) 
 
Conc.M 
Abs at 
λmax 
342nm 
1 5 0.0005 1.38X 10-05 0.124 
2 10 0.001 2.75X 10-05 0.228 
3 15 0.0015 4.14X 10-05 0.345 
4 20 0.002 5.52 X 10-05 0.434 
5 25 0.0025 6.9 X 10-05 0.546 
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Figure (4-30)-: Cefadroxil RS Curve using (ug/ml) Concentrations 
         (curve 2) 
Table (4-28): Absorption of Cefadroxil RS Solutions 3 
Sample # Conc. ug/ml 
Conc. 
%(w/v) 
 
Conc.M 
Abs at 
λmax 
342nm 
1 5 0.0005 1.38X 10-05 0.130 
2 10 0.001 2.75X 10-05 0.230 
3 15 0.0015 4.14X 10-05 0.346 
4 20 0.002 5.52 X 10-05 0.444 
5 25 0.0025 6.9 X 10-05 0.555 
  
  
Figure-(4-31): Cefadroxil RS Curve using (ug/ml) Concentrations 
        (curve 3)  
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4.2.6. Statistics of calibration curves                                                                  
In order to validate the results, statistic analysis was done for each curve 
and the mean value of each curve readings was calculated (Table4-29). 
The mean value of absorbancses was plotted against final concentrations 
to construct a final calibration curve (Figure 4-32).                                   
Table- (4-29): Statistical Analysis of Calibration curves 
Absorbance 
Sample 
# 
 
Conc. 
ug/ml Conc. 
%w/v 
 
Molar Conc 
mol/L 
Abs 
 
Mean 
 
SD RSD% 
1 0.125 
2 0.124 
3 
5 0.0005 
 
 
1.38X10-05 
 0.130 
0.1263 
 
3.2X10-03 
 
2.53 
1 0.230 
2 0.228 
3 
10 
0.001 
 
2.75X10-05 
 0.230 
0.2293 
 
 
1.15X10-03 0.50 
1 0.346 
2 0.345 
3 
15 
0.0015 
 
4.14X10-05 
 0.346 
0.3457 
 
 
0.58X10-03 0.17 
1 0.444 
2 0.434 
3 
20 
0.002 
 
5.52X10-05 
 0.444 
0.4407 
 
 
5.8X10-03 1.32 
1 0.551 
2 0.546 
3 
25 
0.0025 
 
6.9X 10-05 
 0.555 
0.5507 
 
 
4.5X10-03 0.82 
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Figure- (4-32): Cefadroxil Calibration Curve Using Concentrations 
(ug/ml) (Mean of Absorbance) 
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4.2.6.1. Error of the slope and the intercept and determination of 
detection and quantification limits:-  
Error for the slope (b), intercept (a), and the limit of detection and the 
limit of quantification were all determined statistically (Miller and Miller 
2005).  The results are illustrated in table.  Table (4-30) 
 
Sy/x = √ ∑i (Yi - Ŷi) ² / n-2 = √ 7.733×10-5 /3 = 0.00508                              
Sb = Sy/x / √ ∑i (Xi – X`) ² = 0.00508 /√ 250 = 3.2152×10-4 
For t value for (n-2) = 3 the 99% confidence level is 5.84, the 99% confidence 
limit for the b is thus 
b=0.022±5.84×3.2152x10-4 
Slope (b) = 0.022± 0.001878 
Sa = Sy/x√ ∑i Xi² / n∑i (Xi – X`) ² 
Xi  Xi² Yi Ŷi ( Yi -  Ŷi)² ( Xi – 
X`)² 
5 25 0.1263 0.1265 0.004X10-05 100 
10 100 0.2293 0.2325 1.024X10-05 25 
15 225 0.3457 0.3385 5.184X10-05 0 
20 400 0.4407 0.4446 1.520X10-05 25 
25 625 0.5507 0.5506 0.001X10-05 100 
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= 0.00508 √ 1375/5 /250 = 0.00533 
So the confidence limit is  
a = 0.009± 5.84× 0.00533 
Intercept (a) = 0.02835 ± 0.031 
Limit of detection 
Y = YB + 3SB 
Y = 0.009 + 3×0.00508  
Y = 0.02424 
Y= bx + a 
0.02424= 0.022 x +0.009 
So the limit of detection is 0.693µg/ml 
 
Limit of Quantification: 
Y = YB + 10 SB 
Y = 0.009 + 10×0.00508 = 0.0598 
Y = bx + a 
0.0598 = 0.022 x +0.009 
X = 2.31 µg/ml 
So the limit of quantification is 2.31µg/ml  
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Table  (4-31) Absorption of Midroxil® Solutions 1 
Sample # Conc. ug/ml 
Conc. 
%(w/v) 
 
Conc.M 
Abs at 
λmax 
342nm 
1 5 0.0005 1.38X 10-05 0.131 
2 10 0.001 2.75X 10-05 0.239 
3 15 0.0015 4.14X 10-05 0.348 
4 20 0.002 5.52 X 10-05 0.449 
5 25 0.0025 6.9 X 10-05 0.569 
 
     
 Figure-(4-33): Midroxil® Curve using (ug/ml) Concentrations    
(curve 1) 
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Table (4-32):  Absorption of Midroxil® Solutions 2 
Sample # Conc. ug/ml 
Conc. 
%(w/v) 
 
Conc.M 
Abs at 
λmax 
342nm 
1 5 0.0005 1.38X 10-05 0.126 
2 10 0.001 2.75X 10-05 0.237 
3 15 0.0015 4.14X 10-05 0.339 
4 20 0.002 5.52 X 10-05 0.434 
5 25 0.0025 6.9 X 10-05 0.561 
  
  
  
Figure(4-34)-: Midroxil®Curve using (ug/ml) Concentrations               
(curve 2) 
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Table (4-33): Absorption of Midroxil® Solutions 3 
Sample # Conc. ug/ml 
Conc. 
%(w/v) 
 
Conc.M 
Abs at 
λmax 
342nm 
1 5 0.0005 1.38X 10-05 0.127 
2 10 0.001 2.75X 10-05 0.228 
3 15 0.0015 4.14X 10-05 0.348 
4 20 0.002 5.52 X 10-05 0.436 
5 25 0.0025 6.9 X 10-05 0.558 
  
  
Figure (4-35)-: Midroxil®Curve using (ug/ml) Concentrations 
 (curve 3)  
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Table (4-34):  Absorption of Longicef® Solutions 1 
Sample # Conc. ug/ml 
Conc. 
%(w/v) 
 
Conc.M 
Abs at 
λmax 
342nm 
1 5 0.0005 1.38X 10-05 0.131 
2 10 0.001 2.75X 10-05 0.242 
3 15 0.0015 4.14X 10-05 0.349 
4 20 0.002 5.52 X 10-05 0.479 
5 25 0.0025 6.9 X 10-05 0.595 
 
     
 Figure(4-36)-: Longicef® Curve using (ug/ml) Concentrations    
(curve 1) 
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Table (4-35): Absorption of Longicef® Solutions 2 
Sample # Conc. ug/ml 
Conc. 
%(w/v) 
 
Conc.M 
Abs at 
λmax 
342nm 
1 5 0.0005 1.38X 10-05 0.130 
2 10 0.001 2.75X 10-05 0.242 
3 15 0.0015 4.14X 10-05 0.349 
4 20 0.002 5.52 X 10-05 0.455 
5 25 0.0025 6.9 X 10-05 0.582 
  
  
  
Figure( 4-37)-: Longicef®Curve using (ug/ml) Concentrations               
(curve 2) 
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Table (4-36):  Absorption of Longicef® Solutions 3 
Sample # Conc. ug/ml 
Conc. 
%(w/v) 
 
Conc.M 
Abs at 
λmax 
342nm 
1 5 0.0005 1.38X 10-05 0.130 
2 10 0.001 2.75X 10-05 0.249 
3 15 0.0015 4.14X 10-05 0.351 
4 20 0.002 5.52 X 10-05 0.451 
5 25 0.0025 6.9 X 10-05 0.562 
  
  
Figure (4-38)-: Longicef® Curve using (ug/ml) Concentrations 
  (curve 3)  
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4.2.7. Assay of cefadroxil capsules by the Proposed Method:  
Direct standard/sample comparison was used to assay cefadroxil capsules 
by the proposed method (section 3.4.2.3) . The following formula was 
adopted to calculate content of cefadroxil, as % w/w of the tablet 
considering equal sample and standard concentrations:  
A Sample / A STD × 100 
A Sample: Absorbance of the sample  
A STD: Absorbance of the standard 
The results are shown in table 4-36 
4.2.7.1. Assay of capsules by the Proposed Method using conc. 
15ug/ml:- 
Table(4-37)- : Absorbance statistics 
  
Absorbance
1 
Absorbance  
2 
Absorbance 
3 
Mean 
Absorbance 
SD 
Standard 0.346 0.346 0.345 0.3457 0.00058
Midroxil® 
(sample) 0.348 0.346 0.339 0.3443 
0.0047 
Ibidroxil® 
(sample) 0.358 0.357 0.350 0.3550 
0.0044 
Longicef® 
(sample) 0.351 0.349 0.349 0.3497 
0.00115
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Table-(4-38): Content % statistics (Midroxil ® )   
Midroxil ® 
(sample)  
ABS 
 
Content 
(% w/v) 
Mean 
(%w/v)
SD 
(w/v) 
Value range 
 
1 0.348 100.6 
2 0.346 100 
3 0.339 98.3 99.6 1.19 99.6±1.19% 
 
Also the following formula was adopted to calculate content of 
cefadroxil, as % w/w of the tablet directly from the sample and standard 
curves:-  
(Slope of sample curve/Slope of standard curve) x100 
          -Mean slope of the standard curve=0.009 
-Mean slope of the sample curve=0.009 
Content %=( 0.009/.009)x100=100% 
Table- (4-39): Content % statistics (Ibidroxil®)  
Ibidroxil® 
(sample)  
ABS 
 
Content 
(% w/v) 
Mean 
(%w/v)
SD 
(w/v) 
Value range 
 
1 0.358 103.5 
2 0.357 103.2 
3 0.350 101.5 102.7 1.08 102.7±1.08% 
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Table- (4-40): Content % statistics (Longicef ® )  
Longicef ® 
(sample)  
ABS 
 
Content 
(% w/v) 
Mean 
(%w/v)
SD 
(w/v) 
Value range 
 
1 0.351 101.4 
2 0.349 100.9 
3 0.349 101.1 101.13 0.25 101.13±0.25% 
 
4.2.7.2. Assay of cefadroxil capsules using B.P method (HPLC)  
Capsules were assayed using official B.P. method; the results obtained 
are shown in table (4-41). 
 Table- 4-41  
 
Figures (4-39) and (4-40) shows the chromatograms for cefadroxil 
sample compared to similar standard concentration. 
SDMean %Content %Average 
STD area 
Sample 
98.71815252Area 1
961765890Area 2
1.4  97.6 
98
1838811
1805433Area3
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Figure- (4-39): Typical HPLC chromatogram of standard cefadroxil  
 
 
Figure- (4-40): Typical HPLC chromatogram of cefadroxil sample  
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4.2.7.3. Validation of the proposed method compared to BP method 
using F and t value:- 
Calculated t value =  
(Mean of proposed method) - (Mean of HPLC method) / √ (SD² 
pro/n+SD² hplc/n) 
99.6-97.6/√0.47 +0.65 
2/1.06=1.89  
So Calculated t value =1.89, and the 95%confidence limit for 4 degrees 
of freedom is 2.78(tabulated t value)  
F calculated value = (official method SD)² / (proposed method SD)²  
= (1.4)² / (1.19)² =1.38 
confidences limit =  
Mean ± Calculated t x SD/√n =  
99.6± 1.89 x1.19/√3  
So 95% confidence limit =99.6±1.3  
4.2.8. Added recovery (%) by the Proposed Method: 
To determine the added recovery (%) by the proposed method 10 µg/ml 
of standard cefadroxil solution, 10 µg/ml of cefadroxil capsules solution 
and a mixture of both were used (section 3.4.2.4. ). The recoveries were 
calculated according to the following formulae: 
A mix-A sample= A standard (1) 
Recovery (%) = (A standard (1) / A standard) x 100  
 
 
 
119 
 
Table- (4-42): Added recovery (%) of the Proposed Method  
 
Recovery % = 99.37±0.231 
4.2.9. Reproducibility& repeatability:-   
In order to evaluate between - days variation (reproducibility) and 
within day variation (repeatability) 3 different conc. of cefadroxil 
solutions were assessed in three different days table (4-43), and within the 
same day table(4-44). 
Table (4-43):  Cefadroxil RS absorption in Different days 
Absorbance Conc. 
ug/ml Day1 Day 2 Day 3 Mean SD 
10 0.228 0.225 0.223 0.2253 2.51 x 10-3 
15 0.345 0.346 0.346 0.3457 0.58 x 10-3 
20 0.444 0.441 0.439 0.4413 2.5 x 10-3 
 
 
 
  
SDMeanRecovery (%) A standard A standard (1) A sample A mix 
99.50.2180.2170.2170.4341
99.10.2210.2190.2200.4392
0.231 99.37
99.50.2200.2190.2160.4353
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Table -(4-44):- Cefadroxil RS Absorption on the same day 
Absorbance Conc. 
ug/ml 1 2 3 Mean SD 
10 0.225 0.223 0.220 0.2227 2.51x 10-3 
15 0.346 0.346 0.341 0.3443 2.88 x 10-3 
20 0.441 0.438 0.434 0.4377 3.5 x 10-3 
 
The results obtained showed minimal SD, indicating good repeatability 
and reproducibility of the proposed method. 
  
4.2.10. Molar absorbtivity and specific absorbance A1%1cm of 
cefadroxil and  cefadroxil-NaOH reaction product :- 
Table (4-45):-  
 
 
 
 
 
 
 
 
 
  
Proposed 
method
Cefadroxil    
78937260ε (Slope) 
 
220200A1%1cm 
 
342264 Max (nm)λ 
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5.Discussion 
Most of the reported methods of analysis of tobramycin and cefadroxil 
are time consuming, lacking selectivity, require sophisticated equipment 
or not simple for routine analysis. 
Therefore the need for a fast, sensitive, simple and selective methods are 
needed, especially for routine quality control analysis of pharmaceutical 
products containing tobramycin and cefadroxil.  
5.1. Tobramycin:- 
      Tobramycin, like some aminoglycoside, is composed of 2-
deoxystreptamine and tetrahydropyran rings to which amino groups are 
attached. Tobramycin exhibits weak UV- absorption at about 200nm. 
Therefore, a suitable chromogen is needed to react with tobramycin to 
obtain a more UV light absorbing chromophore that can be useful for a 
sensitive spectrophotometric determination of tobramycin in bulk and 
dosage forms. Ascorbic acid is reported to have a selective reaction with 
ammonia, primary aliphatic amines of the type R-CH2-NH2 (λmax 390 
and 532 nm) ((Pesez and Bartos), amino acids with α-aminoacyl function 
λmax  about 400 nm (EL-Obeid et al ). Based on these reports, a simple, 
sensitive and selective assay procedures were proposed for the 
determination of the aminoglycoside, tobramycin in bulk and 
pharmaceutical formulations. It was found to react with tobramycin 
producing a purple colored product absorbing at 390nm and 532nm 
suggesting possibly a π-π and n-π transitions. 
     The mechanism involves initial reaction of one of the amino groups of 
the central cyclohexane ring of tobramycin. The second amino function, 
in the same ring, attacks the carbonyl of the cyclic ester forming a 
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conjugated seven-membered ring with opening of the dehydroascorbic 
acid ring to give the cyclic amide (I) with λmax  at 390. 
Conversion of (I) to the enolate (II) provides more electrons to the 
oxygen atoms of the molecule leading to the bathochromic shift observed 
at  λmax of 532 nm. Structures (I) and (II) exist in equilibrium and their 
enolate oxygens can be protonated in the presence of water resulting in 
changes in the electronic transitions that affect their UV/visible 
spectroscopic properties (Scheme 1). 
 
Figure 5-1: Proposed mechanism for the color – producing reaction 
of tobramycin and ascorbic acid  
5.1.1. Reaction Conditions Optimization 
The different experimental parameters affecting the color 
development were extensively studied to determine the optimal 
conditions for the assay procedure. 
 The optimal volume and concentration for ascorbic acid required 
in the proposed method was found to be 1.0ml of 0.1%w/v in 
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dimethylsulfoxide. The sequence of addition of the reagents as described 
in the method was found to be essential for good reproducibility. Under 
these conditions the color of the complex was formed and was stable for 
at least 24 hours (table4-18, figure 4-22) 
5.1.2. Factors affecting stability of the complex and color formation:- 
5.1.2.1. Effect of water on the reaction 
As reported by Pezes and Bartos, the sample should contain no more than 
1% water in the final volume of the reaction. This was found important 
for high sensitivity and color stability. 
5.1.2.2. Temperature 
The reaction was apparently very slow at room temperature (25  
C).Only the maximum color development was obtained at 100 C and 
this was taken as the optimum temperature for the proposed method. 
5.1.2.3. Reaction time:- 
Estimation of tobramycin-ascorbic acid product reaction time and 
stability :- 
The formation of tobramycin-ascorbic acid product increased with 
increasing time ( table 4-17 , figures 4-19,4-20 &4-21 ); so complex 
formation increased with increasing time of reaction with ascorbic acid. 
Thus 30 minutes heating time was found to be satisfactory for 
reproducible results. 
5.1.2.4. Concentration of the reagent:- 
The reaction rate and maximum absorbance increased with increase in 
ascorbic acid concentration. The optimal concentration for the ascorbic 
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acid reagent required was found to be 1.0 ml of 0.1% w/v in dimethyl 
sulfoxide.  
5.1.2.5. Effect of different solvents:‐ 
The effect of different solvents, namely, dimethylformamide and 
dimethylsulfoxide for ascorbic acid were studied and results obtained are 
shown in table 5-1. 
Table 5.1: Effect of Solvents on the Colour Formation and Intensity 
(tobramycin 48µg/ml) 
Solvents A(mean) λmax R 
Dimethylformamide 
Dimethylsulfoxide 
0.1607 
0.347 
532 
532 
0.991 
0.9991 
 
In the reported method for reaction of ascorbic acid with amines, 
dimethylformamide was used as the suitable solvent.  However from the 
above table it can be seen that the more absorbance intensity was 
observed when dimethylsulfoxide was used as solvent.   
5.1.3. Reproducibility and Repeatability: 
In order to evaluate between - days variation (reproducibility) and within 
day variation (repeatability) 3 different concentrations of tobramycin 
solutions were assessed in different days and the same day using the same 
conditions  .The results showed that proposed method is satisfactorily 
reproducible and repeatable (minimum SD was 0.58 x 10-03) tables (4-
19),  and (4-20).  
125 
 
5.1.4. Minimum Detectable and Quantitative Concentrations: 
On application of the method a minimum detectable and quantitative 
concentrations of 5.5µg/ml and 16.95µg/ml respectively were obtained 
for tobramycin in the proposed method (section4.1.4.1.) 
5.1.5. Added recovery %: 
The accuracy of the  proposed method was checked by recovery-testing. 
The results showed good recovery (100.9%±2.252) table (4-16).It can be 
seen that complete recovery (almost 100%) was obtained by the proposed 
method indicating no interference with the injections excipients &good 
precision and accuracy of the method. 
 5.1.6.Analytical Curves: 
Beer’s law was obeyed in the concentration range of 16 – 80 µg/ml of 
tobramycin, in the final solution with a correlation coefficient r = 0.9986. 
The slope (b) is 0.0068± 0.00144 (n = 5) and the intercept (a) is 0.0067 ± 
0.076. The limit of detection and limit of quantification were 5.5 µg/ml 
and 16.95 µg/ml tobramycin respectively section (4.1.3). 
 The minimum detectable concentration is defined here as the smallest 
amount of an analyte which can be detected by a particular method 
(David, 1999). 
 
 
 
 
126 
 
5.1.7. Study of the Stoichiometry of the Reaction using molar ratio 
method: 
The curve obtained (figure 4-23) shows a break point at tobramycin 
concentration of 20.1x10-4 M (50 µl), equivalent to 20.1x10-4  M ascorbic 
acid (50µl). 
 The molar ratio of tobramycin: ascorbic acid was found to be 1: 1.      
The proposed mechanism of the reaction confirmed this finding, figure  
5-1. 
5.1.8. Interference study:- 
 Ingredients that may be found in multicomponents dosage form as 
Tobradex which contains dexamethasone besides tobramycin were found 
not to interfere with tobramycin-ascorbic acid complex formed.  
Although, dexamethasone gave no absorption reading with ascorbic acid 
at the studied wavelength, but it was found that the absorbance is much 
lower than that of Tobra (about 50%) which suggested an interference 
due to matrix effect. Although the standard addition method is considered 
a possible correction procedure for such possible matrix effect, however, 
no improvement of the results was obtained. Therefore, further study in 
this respect is needed, i.e. extraction process. 
5.2. Cefadroxil:- 
Most of the reported methods of analysis of cefadroxil are time 
consuming, lacking selectivity, require sophisticated equipment or not 
simple for routine analysis. For instance, the most widely used technique 
for its determination is liquid-chromatography.  
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Therefore the need for a fast, sensitive, simple and selective method is 
needed, especially for routine quality control analysis of pharmaceutical 
products containing cefadroxil. The penicillins or the cephalosporines, 
each as a group, share a common structural feature that differs mainly in 
the side chain attached to the nitrogen of the 6-aminopenicillanic acid 
moiety.  
 5.2.1. Proposed mechanism for reaction of cefadroxil and NaOH:-  
 It is well documented that the β-lactam rings of penicillins and 
cephalosporins are cleaved under alkaline conditions to form their 
respective penilloic acids (Y.Yamana et al). Some reports suggested that 
β-lactam antibiotics having free α-amino group form under alkaline 
conditions, a cyclic 2,5 –diketopiperazine derivative as exemplified for 
cefadroxil in (Scheme 2). (EL-Obeid et al). 
  
 
Figure 5-2: Proposed mechanism for reaction of cefadroxil and 
NaOH  
 
The possibly formed 2,5 diketopiperazine is most likely the product 
species that  gave the maximum absorbance at 342 nm reported in this 
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study. This strengthen the suggestion by El Obied et al who pointed out 
that the formation of the 2,5 diketopiperazine is  possible at high NaOH 
concentration and long heating time. The optimum condition for such 
reaction was obtained using 1N NaOH with heating at 100  C for 
30minutes. 
5.2.2. Reaction Conditions Optimization 
The different experimental parameters affecting the product 
formation were studied to determine the optimal conditions for the assay 
procedure. All conditions studied were optimized at room temperature 
(25 ± 1°C). 
 The optimal volume and concentration for NaOH required in the 
proposed method was found to be 1.0 ml of 1N NaOH. Under these 
conditions the reaction product was formed and was stable for at least 3 
hours (table4-24, figure 4-27). 
5.2.3. Reproducibility and Repeatability: 
In order to evaluate between - days variation (reproducibility) and within 
day variation (repeatability) 3 different concentrations of cefadoxil 
solutions were assessed in different days and the same day using the same 
conditions  .The results showed that proposed method is satisfactorily 
reproducible and repeatable (minimum SD was 0.58 x 10-03) tables (4-
42),  and (4-43).  
5.2.4. Minimum Detectable and Quantitative Concentrations: 
On application of the method a minimum detectable and quantitative 
concentrations of 0.693µg/ml and 2.31µg/ml were obtained for cefadroxil 
in the proposed method (section4.2.6.1.). 
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5.2.5. Added recovery %: 
The accuracy of the proposed method was checked by recovery-testing. 
The results showed good recovery (99.37%±0.231) table (4-41).It can be 
seen that complete recovery (almost 100%) was obtained by the proposed 
method indicating no interference with the capsules excipients &good 
precision and accuracy of the method. 
 5.2.6.Analytical Curves: 
Beer’s law was obeyed in the concentration range of 5 – 25 µg/ml of 
cefadroxil, in the final solution with a correlation coefficient r = 0.9993. 
The slope (b) is 0.022 ± 0.001878 (n = 5) and the intercept (a) is 0.009 ± 
0.031 (n=5). The limit of detection and limit of quantification were 0.693 
µg/ml and 2.31µg/ml cefadroxil respectively. 
 The minimum detectable concentration is defined here as the smallest 
amount of an analyte which can be detected by a particular method 
(David, 1999). 
5.2.7. Validation of the proposed method compared to USP method 
using F and t value:-  
In the present work a new spectrophotometric method for determination 
of cefadroxil was developed. The applicability of the proposed method 
was assessed by analyzing the pharmaceutical formulation of 
cefadroxil(midroxil) and statistically the results were compared with LC 
method using F test and t-test.  
For the  proposed method calculated t value was1.89, and the 
95%confidence limit for 4 degrees of freedom is 2.78(t tabulated value) 
So at 95% the confidence limit is 99.6±1.3 (section 4.2.7.3). t-test is used 
to test the accuracy of the new method compared with a reference 
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method, while F-test is used to check the precision of a method compared 
with a reference method (Miller and Miller).  
These results indicate that the proposed method has good precision and 
accuracy compared to the USP method.  
5.2.8. Factors affecting stability of cefadroxil and product 
formation:- 
5.2.8.1 Temperature 
The reaction was apparently very slow at room temperature (25  
C).Only the maximum product formation was obtained at 100 C and 
this was taken as the optimum temperature . Also this indicated that the 
reaction rate increased by increasing temperature; so degradation rate of 
the drug increased with temperature. 
5.2.8.2. Reaction time:- 
 Estimation of cefadroxil-NaOH product reaction time and stability:- 
The results obtained in figure 4-27 showed that heating with 1N NaOH 
for 45minutes in boiling water bath gives higher absorbance and more 
color intensity however heating for 30 minutes was found to be the 
optimal condition to follow the degradation product with reproducible 
results. 
5.2.8.3. Concentration of the reagent:- 
The optimal concentration of NaOH that gave the highest intensity of the 
formed product was found to be 1 N with heating at 100 C. 
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5.3. Comparison between the proposed method and the reported 
method (EL-Obeid et al):-  
Table (5-2)  
  Reported method Proposed method 
1-Procedure steps indirect reaction 
between cefadroxil 
and ascorbic acid 
Direct reaction 
between cefadroxil 
and NaOH 
2-Time of method Longer procedure 
,take about 1 hour 
Shorter procedure 
,take about 30 
minutes 
3-Reagents 0.1 N NaOH,0.1 N 
HCL,DMF and 
ascorbic acid 
1 N NaOH 
4-Heating steps Two heating steps 
̣̣̣̣-10miutes heating 
with NaOH 
-20 minutes heating 
with ascorbic acid 
One heating step(30 
minutes with NaOH) 
5-Stability - indicting  
property 
Delta A method 
applicable 
Not applicable 
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From the above table (5-2), it is clear that the proposed method is more 
simple, less time consuming, less reagent consuming, affordable and from 
which t½ andt90can be calculated. However the reported method has the 
advantage over the second one by having stability indicating property 
using ∆A method which is not applicable in the proposed method. 
5.4. Comparison between the proposed methods and the other 
methods used in the assay of tobramycin and cefadroxil (section 
1.2.5.8. and 1.3.2.9 respectively):- 
-The HPLC method (official method) is the most efficient stability 
indicating method .However, and for developing countries  it is 
considered sophisticated, expensive and time consuming. 
The other reported methods for both are:-  
- Complicated, expensive using many reagents.  
- Depend on selective oxidation of cefadroxil using Ce and Fe(Hesham 
Salem and Gamal A. Saleh)   
5.5 Advantages of the Developed Methods: 
The spectrophotometric methods developed for tobramycin and  
cefadroxil assay in this work were meant to be simple, sensitive and 
easily applicable in routine work. 
. They outweigh most of the reported methods in:  
• Being simple: only direct reaction between tobramycin and 
ascorbic acid, and direct reaction between cefadroxil and 1 N 
NaOH which does not incorporate complicated and long 
procedures. 
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•  Use of simple, non expensive, non sophisticated and available 
instrument  (the spectrophotometer) 
• Use of few reagents. 
• No extraction step.  
• Suitable concentration range. 
• Good stability of the colour (stable for at least 24 hrs).  
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6. Conclusions & Recommendations 
•  From the present study, the developed methods are expected  to be 
suitable as a routine analytical procedure for analysis of  
tobramycin in bulk and in injection form, and analysis of  cefadroxil 
in bulk and in capsule form. The obtained results were comparable 
with BP results. 
• These studies indicated that injection and capsule excipients in the 
dosage forms used in the study do not interfere with the proposed 
methods. 
• The methods can be tried for determination of cefadroxil in 
biological fluids and in other pharmaceutical dosage forms. 
• To elucidate the structure of the reaction product, NMR, elemental 
analysis and mass spectrometry studies are recommended. 
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